CURRICULUM VITAE

Name: Lai Ching Lung

Qualifications: MBBS(Honours)(HK), MD(HK), FRCP(Lond), FRCP(Edin), FRCP(Glas),

FRACP, FHKAM(Medicine), FHKCP

Present Positions Held:

• Simon K Y Lee Professor in Gastroenterology, The University of Hong Kong.

 Chair Professor of Medicine & Hepatology, Department of Medicine, The University of Hong Kong.

Papers and Publications

ISI top 1% scientist ranking 966 out of 19,482 H index 71

International papers on hepatology

- (A) Chronic hepatitis B and C, and hepatocellular carcinoma
- (1) Lam KC, Lin HJ, **Lai CL**, Lam SK, Kwan YL. Isoprinosine in active viral hepatitis. American Journal of Digestive Disease 1978; 23:893-6.
- (2) **Lai CL**, Wu PC, Lam KC, Todd D. Histologic prognostic indicators in hepatocellular carcinoma. Cancer 1979; 44:1677-80.
- (3) Lam KC, Lai CL, Wu PC, Todd D. Aetiological spectrum of liver cirrhosis in the Chinese in Hong Kong. Journal of Chronic Diseases 1980; 33:375-8.
- (4) Wong J, Lam SK, Lee NW, **Lai CL**, Lam P, Ong GB. Immediate operation for acute non-variceal gastrointestinal haemorrhage in patients aged 50 years and over. Australian and New Zealand Journal of Surgery 1980; 50, 2:150-4.
- (5) Lam KC, Lai CL, Ng R, Trepo C, Wu PC. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. New England Journal of Medicine 1981; 304:380-6.
- (6) Chan V, **Lai CL**, Chan TK. Metabolism of anti-thrombin III in cirrhosis and carcinoma of the liver. Clinical Science 1981; 60:681-8.
- (7) Lam KC, Lai CL, Chan WC. Clinical features and natural mortality of chronic active hepatitis B in Hong Kong. Australian and New Zealand Journal of Medicine 1981; 354-8.
- (8) **Lai CL**, Lam KC, Wong KP, Wu PC, Todd D. Clinical features of hepatocellular carcinoma: Review of 211 patients in Hong Kong. Cancer 1981; 47:2746-55.
- (9) Wu PC, **Lai CL**, Lam KC, Ho J. Prednisolone in hepatitis B surface antigen-positive chronic active hepatitis: Histologic evaluation in a controlled prospective study. Hepatology 1982; 2: 777-83.

(10) **Lai CL**, Lam KC, Wong KP, Wu PC, Todd D. Clinical features of hepatocellular carcinoma. Oncology Digest, International Synopses 1982; 1:12.

- (11) **Lai CL**, Ng RP, Lok ASF. The diagnostic value of the ratio of serum gamma-glutamyl transpeptidase to alkaline phosphatase in alcoholic liver disease. Scandinavian Journal of Gastroenterology 1982; 17:41-7.
- (12) Wu PC, **Lai CL**. Hepatic sinusoids in human hepatitis B infection. An electron microscopic study. In: Microcirculation of the alimentary tract. Eds. Koo A, Lam SK & Smaje H. Singapore World Scientific Publications Co., 1983; 351-9.
- (13) Wu PC, **Lai CL**, Lam KC, Lok ASF, Lin HJ. Clear cell carcinoma of liver: An ultrastructural study. Cancer 1983; d2:504-7.
- (14) Lin HJ, Wu PC, **Lai CL**, Winnie Chak. Phosphonoformate inhibition assay of hepatitis B viral DNA polymerase: a micromethod. Clinical Biochemistry 1984; 30:549-52.
- (15) **Lai CL**, Wu PC, Lin HJ. Comparison of two hepatitis B vaccines: Preliminary report of a randomized trial. In: Viral hepatitis B infection in the Western Pacific Region: Vaccine and control. Eds. **Lai CL**, Lam SK & Yeoh EK. Singapore World Scientific Publications Co., 1984; 199-209.
- (16) Lai CL, Wu PC, Yeoh EK, Lok ASF, Lin HJ, Lam SK, Todd D. Hepatocellular carcinoma and the hepatitis B virus. In: Viral hepatitis B infection in the Western Pacific Region: Vaccine and control. Singapore World Scientific Publications Co., 1984; 3-16.
- (17) Wu PC, **Lai CL**, Liddell RHA. Quantitative morphology of mitochondria in hepatocellular carcinoma and chronic liver disease. Archives of Pathology and Laboratory Medicine 1984; 108:914-6.
- (18) **Lai CL.** Chronic hepatitis B related diseases in Hong Kong. Chronicle, Royal College of Physicians of Edinburgh 1985; 157-80.
- (19) Lok ASF, **Lai CL**, Lam SK. HBsAg positive patients: What to do? Medical Progress 1985; 12:7-10.
- (20) Wong KL, **Lai CL**, Wu Pc, Hui WM, Wong KP, Lok ASF. Ultrasonographic studies in hepatic neoplasms: patterns and comparisions with contrast radiological studies. Clinical Radiology 1985; 36:511-6.
- (21) Fowler MJF, Greenfield C, Chu CM, Karayiannis P, Dunk A, Lok ASF, **Lai CL**, Yeoh EK, Monjardino JP, Wankya BM, Thomas HC. Integration of HBV-DNA may not be a prerequisite for the maintenance of the state of malignant transformation an analysis of 100 liver biopsies. Journal of Hepatology 1986; 2:218-29.
- (22) Lok ASF, Lin HJ, Wu PC, **Lai CL**. Serum bile acids and other liver function tests in patients with chronic hepatitis B treated with interferon: An interim report. Proceedings of the IXth International Congress of Infectious Diseases and Parasitic Diseases, Munich July 20-26, 1986. Ed. W Marget, W Lang, E Gabler-Sandberger. MMV Medizin Verlag GmbH Munchen 1986; 87-9.
- (23) Lok ASF, **Lai CL**, Wu PC. Interferon therapy of chronic hepatitis B virus infection in Chinese. Journal of Hepatology 1986; 3(Supp 2):S209-S15.

(24) Lin HJ, **Lai CL**, Wu PC. Serum hepatitis B viral DNA in HBsAg-positive hepatocellular carcinoma treated with interferon or adriamycin. British Journal of Cancer 1986; 54:67-73.

- (25) Lin HJ, Wu PC, **Lai CL**, Leong S. Molecular hybridization study of plasma hepatitis B virus DNA from different carriers. Journal of Infectious Diseases 1986; 154:983-9.
- (26) Lai CL, Yeoh EK, Chang WK, Lo V, Ng L. Use of the hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) in children: Two doses vs three doses of 5 ug regime. An interim report. Journal of Infection 1986; 13 (Suppl A), 19-25.
- (27) Yeoh EK, **Lai CL**, Chang WK, Lo HY. Comparison of the immunogenicity, efficacy and safety of 10 ug and 20 ug of a hepatitis B vaccine: A prospective randomized trial. Journal of Hygiene 1986; 96, 491-9.
- (28) Lok ASF, **Lai CL**, Wu PC, Ng MMT. Response to hepatitis B vaccine in family members of HBsAg carriers. Journal of Medical Virology 1986; 19, 1:33-9.
- (29) Lai CL. Hepatitis B carriers in Hong Kong. Malaysian Journal of Medical Laboratory Sciences 1986; 3.
- (30) Lok ASF, **Lai CL**, Wong KL, Lam WK. Intrahepatic cholestasis associated with enlarged gall bladder. Medical Journal of Australia 1986; 145, 1:36-7.
- (31) Lok ASF, **Lai CL**, Wu PC, Leung EKY, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92:1839-43.
- (32) Lok ASF, **Lai CL**, Wu PC, Wong VCW, Yeoh EK, Lin HJ. Hepatitis B virus infection in Chinese families in Hong Kong. American Journal of Epidemiology 1987; 126:492-9.
- (33) Lin HJ, Wu PC, **Lai CL**. An oligonucleotide probe for detection of hepatitis B virus DNA in serum. Journal of Virology Methods 1987; 15:139-49.
- (34) Lok ASF, Lai CL, Hui WM, Ng MMT, Wu PC, Lam SK, Leung EKY. Risk of transmission of hepatitis B and non-A non-B by fibreoptic upper gastrointestinal endoscopy. Journal of Gastroenterology and Hepatology 1987; 2:175-80.
- (35) **Lai CL**, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. The effect of recombinant alpha₂ interferon in Chinese HBsAg carrier children. The Lancet 1987; 2:877-80.
- (36) **Lai CL**, Gregory PB, Wu PC, Lok ASF, Wong KP, Ng MMT. Hepatocellular carcinoma in Chinese males and females: possible causes for the male predominance. Cancer 1987; 60:1107-10.
- (37) Lok ASF, **Lai CL**, Wu PC, EKY Leung. A randomised controlled trial of recombinant alpha₂ interferon in Chinese patients with chronic hepatitis B virus infection: An interim report. In: Viral hepatitis & liver disease. Ed. AJ Zuckerman. Alan R. Liss Inc., New York, 1988; 848-9.
- (38) **Lai CL**, Lok ASF, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Effect of recombinant alpha₂-interferon in Chinese hepatitis B surface antigen carrier children: A prospective controlled trial. In: Viral hepatitis & liver disease. Ed. AJ Zuckerman. Alan R. Liss, Inc., New York, 1988; 850.

(39) Lok ASF, **Lai CL**, Wu PC. A longitudinal follow-up of asymptomatic HBsAg positive Chinese children. Hepatology 1988; 8:ll30-3.

- (40) Lok ASF, **Lai CL**, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. Hepatology 1988; 8:766-70.
- (41) Lok A, **Lai CL**. Factors determining the development of hepatocellular carcinoma (HCC) in hepatitis B surface antigen carriers: A comparison between families with clusters and solitary cases of hepatocellular carcinoma. Cancer 1988; 61:1287-91.
- (42) **Lai CL**. Hepatocellular carcinoma in Hong Kong Chinese. In: Proceedings of the Centennial Conference, Faculty of Medicine, University of Hong Kong, Hong Kong University Press, 1988; 143-51.
- (43) **Lai CL**, Wu PC, Chan GCB, Lok ASF, Lin HJ. Adriamycin vs no antitumour therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62:479-83.
- (44) Chung HT, **Lai CL**, Wu PC, Lok ASF. Synergism of chronic alcoholism and hepatitis B infection in liver disease. Journal of Gastroenterology and Hepatology 1989; 4:ll-6.
- (45) **Lai CL**, Lok ASF, Lin HJ, Wu PC, Lau JYN, Leung MP, Yeung CY. A review of the use of alpha₂ interferon alone and following steroid withdrawal in HBsAg carrier children. In: Alfa-2b Interferon (Intron A) in the Treatment of Viral Hepatitis, Excerpta Medica, Asia Pacific Congress Series No. 9l, 1989; 34-4l.
- (46) Lau JYN, **Lai CL**, Lin HJ, Lok ASF, Liang RHS, Wu PC, Chan TK, Todd D. Fatal reactivation of chronic hepatitis B virus infection following chemotherapy withdrawal in lymphoma patients. Quarterly Journal of Medicine 1989; 73:911-7.
- (47) Lau JYN, **Lai CL**, Wu PC, Lin HJ. Comparison of two plasma-derived hepatitis B vaccines long term report of a prospective trial. Journal of Gastroenterology and Hepatology 1989; 4:331-7.
- (48) Lok ASF, **Lai CL**. Alpha-fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. Hepatology 1989; 9:110-3.
- (49) **Lai CL**, Wu PC, Lok ASF, Lin HJ, Ngan H, Lau JYN, Chung HT, Ng MMT, Yeoh EK, Arnold M. Recombinant alpha₂ interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a Prospective Randomized Trial. British Journal of Cancer 1989; 60:928-33.
- (50) Lok ASF, **Lai CL**, Wu PC, Lau JYN, Leung EKY, Wong LSK. Treatment of chronic type B hepatitis with interferon: Experience in Chinese patients. Seminars in Liver Diseases 1989; 4:249-53.
- (51) Lau JYN, ASF Lok, **Lai CL**, Wu PC, Lin HJ. Benign recurrent intrahepatic cholestasis in a Chinese girl. Journal of Gastroenterology and Hepatology 1989; 4:581-3.
- (52) Lin HJ, Lau YN, Lai CL, Tam OS. Mutation in a "conserved" sequence in hepatitis B virus DNA specimens from Chinese HBsAg-carrier children. In: Sung JL and Chan DS (ed.) Viral hepatitis and hepatocellular carcinoma, Excerpta Medica, 1990; 92-8.

(53) Lok ASF, **Lai CL**. Acute exacerbation in Chinese patients with chronic hepatitis B virus infection: incidence, etiology and predisposing factors. Journal of Hepatology 1990; 10:29-34.

- (54) Lok ASF, **Lai CL**, Leung EKY. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12: 1266-70.
- (55) Lin HJ, Lai CL, Lau JYN, Chung HT, Lauder I, Fong MW. Evidence for intrafamilial transmission of hepatitis B virus from sequence analysis of mutant HBV DNAs present in two Chinese families. Lancet 1990; 336:208-12.
- (56) Kung AWC, Jones BM, **Lai CL**. Effects on interferon-gamma therapy on thyroid function, 7 lymphocyte subpopulations and induction of autoantibodies. Journal of Clinical Endocrinology and Metabolism 1990; 71:1230-4.
- (57) Liang HS, Lok ASF, **Lai CL**, Chan TK, Todd D, Chiu KW, Ho CS. Hepatitis B infection in patients with lymphomas. Haemotogical Oncology 1990; 8:261-70.
- (58) Lau JYN, Lai CL. Hepatocarcinogenesis. Tropical Gastroenterology 1990; 11:9-24.
- (59) **Lai CL**. Interferons versus doxorubicin in the treatment of hepatocellular carcinoma. Interferons and Cytokines 1990; 15: 6-8.
- (60) Lok ASF, **Lai CL**, Wu PC, Lau JYN, Leung EKY, Wong LSK, Fung YL. Alpha interferon treatment in Chinese patients with chronic hepatitis B. Journal of Hepatology 1990; 11:S121-7.
- (61) Pan HYM, **Lai CL**, Huang CY, Wong KP. Wilson's disease in a patient presenting with skeletal abnormalities. Orthopedics 1990; 75:597-605.
- (62) Lau JYN, **Lai CL**. Interpretation of viral hepatitis serological markers a simplified guide for practitioners. Medical Progress 1990; 17:15-20.
- (63) Lau JYN, Lai CL, Wu PC, Pan HYM, Lin HJ, Todd D. Wilson's disease: a 35 years experience. Quarterly Journal of Medicine 1990; 75:597-605.
- (64) **Lai CL**, Lin HJ, Lau JYN, Lok ASF, Wu PC, Lau JYN, Chung HT, Wong SK, Leung P, Yeung CY. Effect of recombinant alpha₂ interferon with or without prednisone in Chinese HBsAg carrier children. Quarterly Journal of Medicine 1991; 78:155-63.
- (65) Wu PC, **Lai CL**, Choy C. Neutrophils in chronic active hepatitis type B. Archives of Pathology and Laboratory Medicine 1991; 115:930-3.
- (66) Lin HJ, Lai CL, Lau JYN, Chung HT, Lauder I, Fong MW. DNA analysis of a mutant hepatitis B virus (HBV) in four members of a Chinese family: evidence for intrafamilial spread of infection. In: Viral Hepatitis and Liver Diseases. Ed. Hollinger FB, Lemon SM, Margolis H. Williams and Wilkins, Baltimore 1991; 207-9.
- (67) Lau JYN, Lai CL, Wu PC, Chung HT, Lok ASF, Lin HJ. Randomised controlled trial of interferon-gamma in chronic hepatitis B infection. Journal of Medical Virology 1991; 34:184-7.

(68) Lok ASF, Lai CL, Chung HT, Lau JYN. Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and non-malignant hepatitis B virus related chronic liver diseases. Hepatology 1991; 13:834-7.

- (69) Lin HJ, Lai CL, Lauder IJ, Wu PC, Lau K, Fong MW. Application of hepatitis B virus DNA sequence polymorphisms to the study of HBV transmission. Journal of Infectious Diseases 1991; 164:284-8.
- (70) Fang JWS, Lau JYN, Lai CL. Lymphokines. Medical progress 1991; 18 (3):11-20.
- (71) Lok ASF, **Lai CL**. Incidence, neutralizing activity, and clinical significance of interferon antibodies in chronic hepatitis B patients receiving recombinant. interferons. In: Viral Hepatitis and Liver Disease. Ed. Hollinger EB, Lemon SM, Margolis HS. Williams and Wilkins, Battimore 1991; 643-5.
- (72) Chan TM, Cheng IKP, Wong KL, Chan KW, **Lai CL**. Crescentic IgA glomerulonephritis following interleukin 2 therapy for hepatocellular carcinoma of the liver. American Journal of Nephrology 1991; 11:493-6.
- (73) Lok ASF, **Lai CL**. Treatment of chronic hepatitis B virus infection in children. In: Therapy in Liver Diseases. Ed Rodes J and Arroyo V. Doyme SA, Spain 1991; 259-66.
- (74) Lai CL, EK Yeoh, JYN Lau, WK Chang, HJ Lin. Significance of isolated anti-HBc seropositivity by ELISA: implications & the role of radioimmunoassay. Journal of Medical Virology 1992; 36:180-3.
- (75) Lok ASF, Wong A, Sporton S, **Lai CL**, Liu V, Chung HT. Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. Journal of Hepatology 1992; 14:332-4.
- (76) Kung AWC, **Lai CL**, Wong KL, Tam CF. Thyroid functions in patients in interleukin-2 and lymphokine activated pillar cells. Quarterly Journal of Medicine 1992; 82:33-42.
- (77) Carman WF, Ferrao M, Lok ASF, Ma OC, **Lai CL**, Thomas HC. Sequence variation in Chinese isolates of hepatitis B virus. Journal of Infectious Diseases 1992; 165: 127-33.
- (78) Lok ASF, Wu PC, **Lai CL**, Lau JYN, Leung EKY, Wong LSK, Ma OCK, Lauder IJ, Ng CPL, Chung HT. Controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
- (79) Wu PC, Lok ASF, Lau JYN, Lauder IJ, **Lai CL**. Histologic changes in Chinese patients with chronic hepatitis B virus infection following interferon Therapy. American Journal of Clinical Pathology 1992; 98:402-7.
- (80) Lai CL, Lau JYN, Wu PC, Hui WM, Lai ECS, Fan ST, Ngan H, Lin HJ. Subclinical hepatocellular carcinoma in Hong Kong Chinese. Oncology 1992; 49:347-53.
- (81) JWS, Lau JYN, Wu PC, **Lai CL**. Fulminant hepatic failure in non-metastatic renal cell carcinoma. Journal of Digestive Diseases and Sciences 1992; 37: 474-7.
- (82) Wong BCY, **Lai CL**. Ascites in cirrhotic patients: pathophysiology and management. Medical Progress 1992; 19: 18-21.
- (83) Fang JWS, Lau JYN, Lai CL. Neonatal Jaundice: a diagnostic approach Journal of Paediatrics, Obstetrics and Gynaecology 1992; 18:5-8.

(84) Lok ASF, Kwan WK, Moeckli R, Yarbough PO, Chan RT, Reyes GR, **Lai CL**, Chung HT, Lai TST. Seroepidemiological survey of hepatitis E in Hong Kong by recombinant - based enzyme immunoessays. Lancet 1992; 340: 1205-8.

- (85) Chung HT, Lok ASF, **Lai CL**. Re-evaluation of alpha-interferon treatment of chronic hepatitis B using polymerase chain reaction. Journal of Hepatology 1993; 17:208-14.
- (86) Lander IJ, Lin HJ, Lau JYN, Siu TS, **Lai CL**. The variability of the hepatitis B virus genome: statistical analysis and biological implications. Molecular Biology and Evolution 1993; 10:457-70.
- (87) Wu PC, Lau JYN, Lau TK, Lau SK, **Lai CL**. Relationship between intrahepatic expression of hepatitis B viral antigens and histology in Chinese patients with chronic hepatitis B virus infection. American Journal of Clinical Pathology 1993; 100:648-53.
- (88) **Lai CL**, Wong BCY, Yeoh EK, Lin WL, Chang WK, Lin HJ. Five year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasmaderived vaccine in children: immunogenicity and anamnestic responses. Hepatology 1993; 18:763-7.
- (89) Lai CL, Lau JYN, Wu PC, Ngan H, Chung HT, Mitchell SJ, Corbett TJ, Chow AWC, Lin HJ. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993; 17:389-94.
- (90) Ngan H, **Lai CL**, Fan ST, Lai ECS, Yuen WK, Tso WK. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of ciplatin in iodized oil and gel foam. Clinical Radiology 1993; 47:315-20.
- (91) Lin HJ, Lau JYN, Lauder IJ, Shi Ng, **Lai CL**, Hollinger FB. The hepatitis C virus genome: A guide to its conserved sequences and candidate epitopes. Virus Research 1993; 30: 27-41.
- (92) Lin CK, Nicholls J, **Lai CL**. Hepatitis C in Asia. The Journal of the American Medical Association, Southeast Asia 1993; 9: 7-9.
- (93) Lau G, **Lai CL**. Hepatitis B: serology and virology. Australian Chinese Medical Association Journal 1994.
- (94) Fang JWS, Wu PC, **Lai CL**, Lo CK, Meager Ag, Lau JYN. Hepatic expression of interferon-alpha in Chinese patients with chronic hepatitis B virus infection. Digestive Diseases and Sciences 1994; 39:2014-21.
- (95) Fang JW, **Lai CL**, Chung HT, Wu PC, Lau JY. Female children respond to recombinant hepatitis B vaccine with a higher titre than male. J Trop Pediatr 1994; 40(2):104-7.
- (96) McOmish F, Yap PL, Dow BC, Follett EAC, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R, Lin C, **Lai CL**, Leong S, Medgyesi GA, Hejjas M, Kiyokawa H, Fukade IC, Cuypers T, Saeed AA, Al-Rasheed AM, Lin M, Simmonds P. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. Journal of Clinical Microbiology 1994; 32: 884-92.
- (97) Chan TM, Wu PC, Lau JYN, **Lai CL**, Lok ASF, Cheng IKP. Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation 1994; 58: 996-1000.

(98) Chung HT, **Lai CL**, Lok ASF. Pathogenic role of hepatitis B virus in heptitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995; 22:25-9.

- (99) Chan TM, Wu PC, Lok ASF, **Lai CL**, Cheng IKP. Clinicopathological features of hepatitis C virus antibody negative fatal chronic hepatitis C after renal transplantation. Nephron 1995; 71:213-7.
- (100) Cheng IKP, Ho SKN, Fang GX, Chan DTM, **Lai CL.** The usefulness of measurement of serum viral DNA using DOT-BLOT hybridization and polymerase chain reaction in renal transplant patients with hepatitis B viral infection. Transplantation Proceedings 1996.
- (101) Wu PC, Fang JWS, **Lai CL**, Lau SK, Lo CK, Lai A, Lau JYN. Hepatic expression of hepatitis B virus genome in chronic hepatitis B virus infection. American Journal of Clinical Pathology 1996; 105:87-95.
- (102) Ngan H, Lai CL, Fan ST, Lai EC, Yuen WK, Tso WK. Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma A 4-year follow-up. Journal of Vascular and Interventional Radiology 1996; 7:419-25.
- (103) Tse HF, Lau CK, Lau YK, **Lai CL.** Transesophageal Echocardiography in the detection of Inferior Vena Cava and Cardiac Metastasis in Hepatocellular Carcinoma. Clinical Cardiology 1996; 19:211-13.
- (104) Wu PC, Fang JWS, Lau VKT, **Lai CL**, Lo CK, Lau JYN. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers: clinical and biological implications. American Journal of Pathology 1996; 149:1167-1175.
- (105) **Lai CL**. New antiviral treatment for chronic hepatitis B. In: Update on Hepatobiliary Diseases 1996. Falk Symposium Series, Kluwer Academic Publishers, Lancaster, England 1996; 54-66.
- (106) Lo CM, Lo RJW, Lai CL, Fan ST, Wong J. Liver transplantation from cadaveric and living donors. Transplantation Proceedings 1996; 28(3):1659-60.
- (107) Lo CM, Fan ST, Chan JKF, Wei W, Lo RJW, **Lai CL**. Minimum graft volume for successful adult-to-adult living donor liver transplantation for fulminant hepatic failure. Transplantation 1996; 62:696-698.
- (108) Prescott LE, Simmonds P, **Lai CL**, Chan NK, Pike I, Yap PL, Lin CK. Detection and clinical features of hepatitis C virus type 6 infections in blood donors from Hong Kong. Journal of Medical Virology 1996; 50:168-175.
- (109) Fan ST, Lo CM, Chan KL, Lo R, Saing H, Wei W, **Lai CL**, Tsoi-NS, Ngi I, Chan JK, Chau MT, Tso WK, Wong J. Liver transplantaion-perspective from Hong Kong. Hepatogastroenterology 1996; 43(10):893-7.
- (110) Lo CM, Chan KL, Fan ST, Saing H, Lo RJ, Tsoi NS, Wei W, **Lai CL**. Living donor liver transplantation: the Hong Kong experience. Transplantation Proceedings 1996; 28(4):2390-2.
- (111) Lai CL, Ching CK, Tung AKM, Li E, Young J, Hill A, Wong BCY, Dent J, Wu PC. Lamivudine is effective in suppressing HBV DNA in Chinese HBsAg carriers. A placebo-controlled trial. Hepatology 1997; 25/1:241-4.

- (112) Lau GKK, Lok ASF, Liang RHS, **Lai CL**, Chiu EKW, Lau YL, Lam SK. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997; 25:1497-1501.
- (113) Yuen MF, **Lai CL**. Combating hepatitis B. Asian Hospital and Healthcare Management, 1997.
- (114) Lai VCH, **Lai CL**, Low BG, Lau JYN, Wu PC. Quantitative detection of serum HBV DNA in Chinese patients. Journal of Viral Hepatitis, 1997; 4:359-362.
- (115) Lai CL. Public health aspects of chronic hepatitis B in Hong Kong. In: Zukerman A ed. Hepatitis B in the Asian-Pacific Region. Vol 1. Screening, diagnosis and Control. Royal College of Physicians of London, 1997; 79-87.
- (116) Lai CL and Yuen MF. Monitoring disease progression and outcome of therapy in chronic hepatitis B. In: Zukerman A ed. Hepatitis B in the Asian-Pacific Region. Vol 1. Screening, diagnosis and Control. Royal College of Physicians of London, 1997; 155-167.
- (117) **Lai CL**, Lau JYN. Hepatocarcinogenesis. Update on liver diseases. Research Forum on the Digestive System 1997.
- (118) Ngan H, Tso WK, **Lai CL**, Fan ST. The role of hepatic arterial embolization in the treatment of spontaneous rupture of hepatocellular carcinoma. Clinical Radiology 1997; 53:338-341.
- (119) Fan ST, Lo CM, Lo RJ, Fung KY, Wei WL, Chen YB, **Lai CL**, Ng IO, Yuen KY, Chan J, Wong J. Management of fulminant hepatic failure at Queen Mary Hospital. Chin Med J Engl 1997; 110(6):482-4.
- (120) Chan TM, Wu PC, Lau JYN, Lok ASF, **Lai CL**, Cheng IKP. Interferon treatment for hepatitis C virus infection in patients on hemodialysis. Nephrol Dial Transplant 1997; 12(7):1414-9.
- (121) Lo CM, Fan ST, Liu CL, Wei WI, Lo RJW, Lai CL, Chan JKF, Ng IOL, Fung A, Wong J. Adult-to-adult living donor liver transplantation using extended right lobe grafts. Annals of Surgery 1997; 226(3):261-270.
- (122) **Lai CL**, Chien RN, Leung NWY, Chang TT, Kwan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF, Asian Hepatitis Lamivudine Study Groups. A one year trial of lamivudine for chronic hepatitis B. New England Journal of Medicine 1998; 339(2):61-68.
- (123) **Lai CL**, Yuen MF. Public health policy for hepatitis B infection in Hong Kong. In: Zukerman A ed. Hepatitis B in the Asian-Pacific. Vol 2. Chronic hepatitis B prevention strategies. Royal College of Physicians of London 1998; 121-125.
- (124) **Lai CL**, Yuen MF. The treatment of chronic hepatitis with lamivudine. In:. In: Zukerman A ed. Hepatitis B in the Asian-Pacific. Vol 2. Chronic hepatitis B prevention strategies. Royal College of Physicians of London 1998; 169-177.
- (125) Chan TM, Wu PC, Li FK, **Lai CL**, Cheng IKP, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115:177-181.

- (126) Lai CL, Yuen MF. Hepatocellular carcinoma and its early detection in Hong Kong. In: Zukerman A ed. Hepatitis B in the Asian-Pacific. Vol 2. Chronic hepatitis B prevention strategies. Royal College of Physicians of London, 1998; 149-157.
- (127) Chan TM, Lau JYN, Wu PC, **Lai CL**, Lok ASF, Cheng IKP. Hepatitis C virus genotypes in patients on renal replacement therapy. Nephrol Dial Transplant 1998; 13:731-734.
- (128) Lo CM, Fan ST, Liu CL, Chan KL, Ng IOL, **Lai CL**, Lau GKK, Fung SKY, Wong J. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. Transplantation Proceedings 1998; 30:3587-3588.
- (129) Lo CM, Fan ST, Liu CL, Lo RJW, **Lai CL**, Lau GKK, Chan JKF, Ng IOL, Wong J. Five-year experience with the development of a liver transplant program in Hong Kong. Transplantation Proceedings 1998; 30:3247-3248.
- (130) Lai V, Guan R, Wood ML, Lo SK, Yuen MF, Lai CL. Nucleic acid-based cross-linking assay for the detection and quantification of hepatitis B virus DNA. Journal of Clinical Microbiology 1999; 37:161-164.
- (131) Yuen MF, Lau CS, Lau YL, Wong WM, Cheng CC, Lai CL. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999; 29(4):1248-51.
- (132) **Lai CL**. Antiviral therapy for hepatitis B and C. Journal of Gastroenterology and Hepatology 1999; 14:S19-S21.
- (133) Lai CL, Yuen MF. Screening and selection of patients for treatment with lamivudine. In: Zukerman A ed. Hepatitis B in the Asian-Pacific Region. Vol 3. New insights into managing and treating patients. Royal College of Physicians of London, 1999; 21-25.
- (134) **Lai CL**, Yuen MF. Adults with and without evidence of liver disease. In: Zukerman A ed. Hepatitis B in the Asian-Pacific Region. Vol 3. New insights into managing and treating patients. Royal College of Physicians of London, 1999; 37-39.
- (135) **Lai CL**, Yuen MF, Chan TM. Lamivudine in the treatment of fibrosing cholestatic hepatitis. In: Zukerman A ed. Hepatitis B in the Asian-Pacific Region. Vol 3. New insights into managing and treating patients. Royal College of Physicians of London, 1999; 49-50.
- (136) Lai CL, Yuen MF. Resistance to lamviduine, its clinical relevance and management. In: Zukerman A ed. Hepatitis B in the Asian-Pacific Region. Vol III. New insights into managing and treating patients. Royal College of Physicians of London, 1999; 93-97.
- (137) Fan ST, Lo CM, Cheung ST, **Lai CL**, Ng IOL. Lamivudine in liver transplantation. In: Zukerman A ed. Hepatitis B in the Asian-Pacific Region. Vol 3. New insights into managing and treating patients. Royal College of Physicians of London, 1999; 76-80.
- (138) Lo CM, Fan ST, **Lai CL**, Liu CL, Yuen MF, Ng IOL, Wong J. Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. Transplantation Proceedings 1999; 31(1-2):535-6.
- (139) Yuen MF, Lai CL. Debates in hepatitis: How to assess HBV DNA reductions in association with therapy. Viral Hepatitis Reviews 1999; 5(3):159-175.

- (140) Yuen MF, Lim WL, Cheng CC, Lam SK, Lai CL. Twelve-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs plasmaderived vaccine without booster doses in children. Hepatology 1999; 29(3):924-7.
- (141) Wu PC, Lai VC, Fang JW, Gerber MA, **Lai CL**, Lau JY. Hepatocellular carcinoma expressing both hepatocellular and biliary markers also expresses cytokeratin 14, a marker of biopotential progenitor cells. [letter] Journal of Hepatology 1999; 31(5):965-966.
- (142) Wu PC, Lau VK, Fang JW, Lai VC, **Lai CL**, Lau JY. Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver 1999; 19(5):444-451.
- (143) Chan AOO, Lam CM, Yuen ST, **Lai CL**, Lam SK. Cholangiographic appearance of hepatic inflammation pseudotumour and its pathogenic implication. Endoscopy 1999; 31(5):S39-40.
- (144) Chan TM, Ho SKN, **Lai CL**, Cheng IKP, Lai KN. Lymphocyte subsets in renal allograft recipients with chronic hepatitis C virus infection. Nephrology Dialysis Transplantation 1999; 14(3):717-22.
- (145) Lo CM, Fan ST, Liu CL, Wei WI, Chan JK, **Lai CL**, Lau GKK, Wong J. Applicability of liver donor liver transplantation to high-urgency patients. Transplantation 1999; 67(1):73-7.
- (146) Fan ST, Lo CM, Liu CL, Yong BH, **Lai CL**. Causes of hospital death in patients undergoing liver transplantation. HPB 1999; 1(2) 85-89.
- (147) Cheng CC, **Lai CL**. Non-alcoholic steatohepatitis. Journal of the American Medical Association, SE Asia 1999.
- (148) **Lai CL**, Yuen MF. Profound suppression of hepatitis B virus replication with lamivudine. Journal of Medical Virology 2000; 61(3):367-373.
- (149) Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, **Lai CL**. Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31(1):201-206.
- (150) Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, **Lai CL**, on behalf of the Asia Hepatitis Lamivudine Study Group. Efficacy and tolerability of two years of lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119(1):172-180.
- (151) **Lai CL**, Yuen MF. Natural history of chronic hepatitis B virus infection. Journal of Gastroenterology and Hepatology 2000; 15 (Suppl.):E20-E24.
- (152) **Lai CL**, Yuen MF. Clinical experience and follow up with lamivudine in the Asian population. In: Schinazi, Rice and Sommadossi ed. Frontiers in Viral Hepatitis 2000.
- (153) Yuen MF, **Lai CL**. Prevention and management of hepatitis B: global scenario. Indian Journal of Gastroenterology 2000; 19 Suppl 3: C3-5.
- (154) **Lai CL**, Yuen MF. Prevention and management of hepatitis B: global scenario. Proceedings of the 2nd National Single Theme Symposium on Hepatitis B Infection in India Therapeutic Options and Prevention Strategies. New Delhi, September 2 and 3, 2000.

(155) Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CGC, **Lai CL**. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31(2):330-335.

- (156) Lo CM, Fan ST, Liu CL, Ng IOL, Lam BK, Yong BH, Lai CL, Lau GKK. More effective immunosuppression with the use of FK506 after liver transplantation. Transplantation Proceedings 2000; 32(7):2269-2270.
- (157) Lo CM, Fan ST, Liu CL, **Lai CL**, Lau GKK, Yong BH, Ng IOL, Young K, Chan JK, Wong J. Liver transplantation in Hong Kong a wider application. Transplantation Proceedings 2000; 32(7):2141.
- (158) Chan DTM, Lok ASF, **Lai CL**, Cheng IKP, Lai KN. Hepatitis C after renal transplantation. Transplantation Proceedings 2000; 32:1799-1800.
- (159) Lo CM, Cheung ST, Lai CL, Liu CL, Ng IOL, Yuen MF, Fan ST, Wong J. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001; 233(2):276-281.
- (160) Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, **Lai CL**. Long-term follow-up of interferon-alpha treatment in Chinese patients with chronic hepatitis B infection: the effect on HBeAg seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34(1):139-145.
- (161) Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Lim SG, Wu PC, Dent JC, Edmundson S, Condreay LD, Chien RN on behalf of the Asia Hepatitis Lamivudine Study Group*. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after three years of therapy. Hepatology 2001; 33:1527-1532.
- (162) Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, **Lai CL**. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34(4):785-791.
- (163) Yuen MF, Chan TM, Hui CK, Chan AO, Ng IO, **Lai CL**. Acute pancreatitis complicating acute exacerbation of chronic hepatitis B infection carries a poor prognosis. J Viral Hepat. 2001; 8(6):459-464.
- (164) de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, **Lai CL**, Gadano A, Lee Y, Mazzotta F, Thomas N, DeHertogh D. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 2001; 34(3):578-582.
- (165) Yuen MF, **Lai CL**. Treatment for chronic hepatitis B. The Lancet Infectious Disease 2001; 1:232-241.
- (166) Yuen MF, Wu PC, Lai VCH, Lau JYN, **Lai CL**. Expression of c-Myc, c-Fos, and c-Jun in Hepatocellular Carcinoma. Cancer 2001; 91(1):106-112.
- (167) Chan AOO, Yuen MF, Hui CK, Tso WK, **Lai CL**. A prospective study on the complications of transcatheter intraarterial lipoidal chemoembolisation for hepatocellular carcinoma. Cancer 2001; 94(6):1747-1752.

(168) Yuen MF, Hui CK, Yuen JCH, Young JLP, **Lai CL**. The accuracy of SM-HCV rapid test for the detection of antibody to hepatitis C virus (Anti-HCV). American Journal of Gastroenterology 2001; 96(3):838-841.

- (169) Hui CK, Yuen MF, Ng IOL, Tsang KWT, Fong GCY, **Lai CL**. Low molecular weight heparin-induced liver toxicity. Journal of Clinical Pharmacology 2001; 41:1-4.
- (170) Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, **Lai CL**, Ueda R, Miyakawa Y, Mizokami M. Hepatitis B Virus of Genotype B with or without Recombination with Genotype C over the Precore Region plus the Core Gene. Journal of Virology 2002; 76(12):5985-5992.
- (171) Perrillo RP, **Lai CL**, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36:186-194.
- (172) **Lai CL**, Yuen MF, Hui CK, Garrido-Lestache S, Cheng CTK, Lai YP. Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: results of 24 weeks of therapy. Journal of Medical Virology 2002; 67:334-338.
- (173) Yuen MF, Sablon E, Yuan HJ, Hui CK, Wong DKH, Doutreloigne J, Wong BCY, Lai CL. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. Journal of Infectious Diseases 2002; 186(9):1335-1338.
- (174) **Lai CL,** Rosmawati M, Lao J, Vlierberghe HV, Anderson FH, Thomas N, DeHertogh D. Entecavir is superior to lamivdine in reducing HBV DNA in patients with chronic hepatitis B infection. Gastroenterology, 2002; 123(6):1831-1838.
- (175) Wong WM, Ng IOL, Ooi GC, Hui CK, Fan ST, Trendell-Smith N, **Lai CL.** Severe hypoalbuminaemia in the cirrhosis of liver. Journal of Clinical Gastroenterology; 2002.
- (176) Yuen MF, Hon C, Hui CK, Siu CW, **Lai CL.** Recombinant interferon alpha 2b in a patient with metastatic hepatocellular carcinoma. Journal of Clinical Gastroenterology 2002; 35(3):272-275.
- (177) Yuen MF, Poon RT, **Lai CL**, Fan ST, Lo CM, Wong KW, Wong WM, Wong BCY. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36(3):687-691.
- (178) Yuen MF, Chan TM, Yip TP, Yuen JC, Ho SK, **Lai CL**. Prevalence and significance of hepatitis GB virus-c/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. Digestive Diseases and Sciences 2002; 47(2):432-437.
- (179) Hui CK, Yuen MF, Wong WM, Lam SK, **Lai CL**. Mirtazapine-induced hepatoxicity. Journal of Clinical Gastroenterology 2002; 35(3):270-271.
- (180) Ng FH, Wong WM, Wong BCY, Kng C, Wong SY, Lai KC, Cheng CS, Yuen WC, Lam SK, Lai CL. Sequential intravenous/oral antibiotic versus continuous intravenous antibiotic in the treatment of pyogenic liver abscess. Alimentary Pharmacology & Therapeutics 2002; 16(6):1083-1089.

(181) Yeung CK, Yuen MF, Chan TM, Lai CL. Acute Hepatitis as a presentation of acute appendicits in an immunocompromised patient. Journal of Clinical Gastroenterology 2002; 35(2):203-204.

- (182) Wong WM, Wong BCY, Hui CK, Ng M, Lai KC, Tso WK, Lam SK, Lai CL. Pyogenic liver abscess retrospective analysis of 80 cases over a 10-year period. Journal of Gastroenterology and Hepatology, 2002; 17(9):1001-1007.
- (183) Hui CK, Yuen MF, Wong WM, Lam SK, **Lai CL**. Mirtazapine induced hepatotoxicity. Journal of Clinical Gastroenterology 2002; 35(3):270-1.
- (184) **Lai CL**, Lam SK. Memoir on hepatitis and liver disease history in Hong Kong. J Gastroenterology & Hepatology 2002; 17 Suppl:S510.
- (185) Yuen MF, Yuan HJ, Hui CK, Wong DKH, Wong WM, Chan AOO, Wong BCY, **Lai CL**. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: Implications for antiviral therapy. Gut 2003; 53: 416-9.
- (186) **Lai CL**, Dienstag JL, Schiff E, Leung NWY, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy of patients with chronic hepatitis B. Clinical Infectious Diseases 2003; 15; 36:687-696.
- (187) Yuen MF, Sablon E, Yuan HJ, Wong DK, Hui CK, Wong BC, Chan AO, **Lai CL**. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003; 37:562-567.
- (188) Yuen MF, **Lai CL**. Current and future antiviral therapy for chronic hepatitis B. Journal of Antimicrobial Chemotherapy 2003; 51:481-485.
- (189) Hui CK, Yuen MF, Tso WK, Ng IOL, Chan AOO, Lai CL. Cholangiocarcinoma in liver cirrhosis. Journal of Gastroenterology & Hepatology 2003; 18:337-341.
- (190) Yuen MF, Sablon E, Wong DKH, Yuan HJ, Wong BCY, Chan AOO, **Lai CL**. Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation. Clin Infect Dis 2003 15; 37(4):593-597.
- (191) Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong KH, Doutreloigne J, Bogaerts V, Wong BCY, Fan ST, **Lai CL**. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis 2003; 36:979-984.
- (192) Lai CL, Ratzlu V, Yuen MF, Poynard T. Seminar: Viral hepatitis B. Lancet 2003; 362:2089-2094.
- (193) Poynard T, Yuen MF, Ratziu V, **Lai CL**. Seminar: Viral hepatitis C. The Lancet 2003; 362:2095-2100.
- (194) Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Gish RG, Ueda R, Miyakawa Y, Mizokami M. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003; 124:925-32.
- (195) Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003; 75(3 Suppl):S41-44.

(196) Lo CM, Fung JT, Lau Gkk, Liu CL, Cheung ST, **Lai CL**, Fan ST, Wong J. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37:36-43.

- (197) Liu CL, Fan ST, Lo CM, Wei WI, Yong BH, **Lai CL**, Wong J. Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation 2003; 76:1174-1179.
- (198) Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ, Wong DK, Sum SM, Ng IO, Fan ST, **Lai CL.** Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. Journal of Hepatology 2003; 39:850-855.
- (199) Yuen MF, Wong DKH, Sablon E, Yuan HJ, Sum SM, Hui CK, Chan AOO, Wong BCY, Lai CL. Hepatitis B virus genotypes B and C do not affect the anti-viral response to lamivudine. Antiviral Therapy 2003; 8(6):531-534.
- (200) Schiff ER, **Lai CL**, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann HL, Samuel D, Zeuzem S, Lilly L, Rendina M, Villeneuve JP, Lama N, James C, Wulfsohn MS, Namini H, Westland C, Xiong S, Choy GS, Van Doren S, Fry J, Brosgart CL; Behalf of the Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology. 2003; 38:1419-27.
- (201) Lok ASF, **Lai CL**, Leung N, Yao GB, Cui SY, Schiff ER, Dienstage JL, Heathcote J, Little NR, Griffiths DA, Gardner SD, Castiglia M. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
- (202) Yuen MF, Tanaka Y, **Lai CL**. Hepatitis B genotypes in chronic hepatitis B and lamivudine therapy. Intervirology 2003; 46:373-376.
- (203) Yuen MF, Chan AOO, Wong BCY, Hui CK, Ooi GC, Tso WK, Yuan HJ, Wong DKH, Lai CL. Transarterial chemoembolization for inoperable, early-stage hepatocellular carcinoma in patients with Child-Pugh grade I and II: Results of a comparative study in 96 Chinese patients. Am J Gastroenterology 2003; 98:1181-1185.
- (204) Yuen MF, Ooi CGC, Hui CK, Wong WM, Wong BCY, Chan AOO, Lai CL. A Pilot Study of Transcatheter Arterial Interferon Embolisation for Hepatocellular Carcinoma. Cancer 2003; 97:2776-2782.
- (205) Yuen MF, **Lai CL**. Screening for Hepatocellular Carcinoma: Survival Benefit and Cost-effectiveness. Ann Oncol 2003; 14:1463-1467.
- (206) Hui CK, Yuen MF, Tso WK, Ng IOL, Chan AOO, **Lai CL**. Cholaniocarcinoma in liver cirrhosis. J Gastroenterology & Hepatology 2003; 18(3):337-41.
- (207) Hui CK, Yuen MF, Sablon E, Chan AOO, Wong BCY, **Lai CL**. Interferon and ribavirin therapy for chronic hepatitis C genotype 6: A comparison with genotype 1. J Infect Dis 2003; 187:1071-1074.
- (208) Wong WM, Hui CK, Yuen MF, **Lai CL**, Ng IO, Trendell-Smith N, Ooi GC, Fan ST. Reversal of protein-losing enteropathy by liver transplantation. J Clin Gastro 2003; 36(1):86-7.

(209) Liu CL, Fan ST, Lo CM, Wei WI, Yong BH, **Lai CL**, Wong J. Live donor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation 2003; 76:1174-1179.

- (210) Poynard T, Mathurin P, **Lai CL**, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38(3):257-265.
- (211) Chan AO, Ng IO, Lam CM, Shek TW, **Lai CL**. Cholestatic jaundice caused by sequential carbimazole and propylthiouracil treatment for thyrotoxicosis. Hong Kong Med J 2003; 9:377-380.
- (212) Wong WM, Ho JC, Hung IF, Ng W, Lam YM, Tam WO, Wong BC, Wong PC, Lai CL, Lam WK, Lam SK, Tsang KW, Ooi GC, Ho PL, Mok T, Chan J. Temporal patterns of hepatic dysfunction and disease severity in patients with SARS. JAMA. 2003; 290:2663-5.
- (213) Yuen MF, **Lai CL**. Specific considerations in the design of hepatitis B virus clinical studies in the Far East. Methods in Molecular Medicine 2004; 96:457-464.
- Yuen MF, Tanaka Y, Mizokami M, Yuen JCH, Wong DKH, Yuan HJ, Sum SM, Chan AOO, Wong BCY, **Lai CL**. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: A case control study. Carcinogenesis 2004; 25:1593-1598.
- (215) Sum SSM, Wong DKH, Yuen MF, Yuan HJ, Yu J, **Lai CL**, Ho D, Zhang LQ. Real-time PCR assay using molecular beacon for quantitation for hepatitis B virus DNA. Journal of Clinical Microbiology 2004; 42:3438-40.
- (216) Yuan HJ, Yuen MF, Wong DKH, Sum SSM, **Lai CL**. Clinical evaluation of the Digene hybrid capture II test and the COBAS AMPLICOR monitor test for determination of hepatitis B virus DNA levels. Journal of Clinical Microbiology 2004; 42:3513-7.
- (217) Pang A, Yuen MF, Yuan HJ, **Lai CL**, Kwong YL. Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis e antigen seroconversion. J Hepatol. 2004; 40(6):1008-17.
- (218) Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, **Lai CL**. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004 39(6):1694-701.
- (219) Yuen MF, Sablon E, Tanaka Y, Kato T, Mizokami M, Doutreloigne J, Yuan HJ, Wong DK, Sum SM, **Lai CL**. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. J Hepatol 2004; 41:119-25.
- (220) Mohamed R, Desmond P, Suh DJ, Amarapurkar D, Gane E, Guangbi Y, Hou JL, Jafri W, Lai CL, Lee CH, Lee SD, Lim SG, Guan R, Phiet PH, Piratvisuth T, Sollano J, Wu JC. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 2004; 19:958-69.
- (221) Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, Yuen MF, Chao GC, Myers MW. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004; 40:719-26.

- (222) Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, **Lai CL**. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004; 40:727-37.
- (223) Wong DK, Yuen MF, Tse E, Yuan H, Sum SS, Hui CK, **Lai CL**. Detection of intrahepatic hepatitis B virus DNA and correlation with hepatic necro-inflammation and fibrosis. J Clin Microbiol 2004; 42:3920-4.
- (224) Yuen MF, Yuan HJ, Sablon E, Wong DK, Chan AO, Wong BC, **Lai CL**. Long-term follow-up study of Chinese patients with YMDD mutations: significance of hepatitis B virus genotypes and characteristics of biochemical flares. J Clin Microbiol 2004; 42:3932-6.
- (225) Yuen MF, Ng IO, Fan ST, Yuan HJ, Wong DK, Yuen JC, Sum SS, Chan AO, **Lai CL**. Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol 2004; 99:2032-7.
- (226) Yuen MF, Wong DK, Yuan HJ, Sum SM, Lai CL. HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection. J Clin Microbiol 2004; 42:4882-4.
- (227) Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, **Lai CL**. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2004; 2:941-5.
- (228) Chang TT, **Lai CL**, Chien RN, Guan R, Lim SG, Lee CM, Ng KY, Nicholls GJ, Dent JC, Leung NW. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19:1276-82.
- (229) Yuen MF, **Lai CL**. Adefovir dipivoxil in chronic hepatitis B infection. Expert Opin Pharmacother 2004; 5:2361-7.
- (230) Yuen MF, Fung SK, Tanaka Y, Kato T, Mizokami M, Yuen JC, Wong DK, Yuan HJ, Sum SM, Chan AO, Wong BC, **Lai CL**. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 2004; 42:5036-40.
- (231) Zhang L, Chen Z, Cao Y, Yu J, Li G, Yu W, Yin N, Mei S, Li L, Balfe P, He T, Ba L, Zhang F, Lin HH, Yuen MF, **Lai CL**, Ho DD. Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol 2004; 78:13591-9.
- (232) Yuen MF, **Lai CL**. Treatment for hepatitis B: a public health perspective. J Clin Gastroenterol. 2004; 38(10 Suppl):S134-5.
- (233) **Lai CL.** Therapeutic advances in chronic hepatitis B. J Gastroenterol Hepatol. 2004; Suppl: S5-9.
- (234) Chan AOO, Yuen MF, Lam CM, Fong CY, Wong BCY, **Lai CL**. Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. Alimentary Pharmacology & Therapeutics 2004; 19:401-406

(235) Pang R, Yuen J, Yuen MF, **Lai CL**, Lee TK, Man K, Poon RT, Fan ST, Wong CM, Ng IO, Kwong YL, Tse E. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene. 2004; 3(23):4182-6.

- (236) Chau TN, Lee KC, YAO h, Tsang TY, Chow TC, Yeung YC, Choi KW, Tso YK, Lau T, Lai ST, Lai CL. SARS-associated viral hepatitis by a novel coronavirus: Report of three cases. Hepatology 2004; 39:302-310.
- (237) Hui CK, Lai KC, Yuen MF, Wong WM, Chan AOO, Ng M, Chan CK, Cheung WW, Lam SK, Lai CL, Wong BCY. The role of cholecystectomy in reducing recurrent gallstone pancreatitis. Endoscopy 2004; 36:206-211.
- (238) Lo CM, Cheung ST, Ng IOL, Liu CL, Lai CL, Fan ST. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: Successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transplantation 2004; 10:557-563.
- (239) Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, **Lai CL**, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 2004, 10(6):728-33.
- (240) Lo CM, Fan ST, Liu CL, Yong BH, Wong Y, Lau GK, Lai CL, Ng IO, Wong J. Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg. 2004, 240(1):151-8.
- (241) Yuen MF, Ip P, Ng WK, **Lai CL**. Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). J Hepatol. 2004; 41:686-7.
- (242) Yuen MF, Yuan HJ, Wong DKH, Yuen JCH, Wong WM, Chan OO, Wong BCY, Lai KC, Lai CL. Prognostic Determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 2005, 54(11):1610-1624.
- (243) Yuen MF, Chow DH, Tsui K, Wong BC, Yuen JC, Wong DK, **Lai CL**. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther. 2005 Apr 1;21(7):841-9.
- (244) Yuan HJ, Yuen MF, Wong DK, Sum SM, Doutreloigne J, Sablon E, **Lai CL**. Determinants for the occurrence of acute exacerbation of hepatitis B virus infection in Chinese patients after HBeAg seroclearance. J Clin Microbiol. 2005, 43(4):1594-9.
- (245) Yuen MF, Wong DK, Sum SS, Yuan HJ, Yuen JC, Chan AO, Wong BC, Lai CL. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol. 2005, 100(5):1099-103.
- (246) Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann H-W, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA, and the Telbivudine Phase II Investigator Group. A One-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients with HBeAg-Positive Chronic Hepatitis B. Gastroenterol 2005, 129:528-536.
- (247) Yuan HJ, Yuen MF, Ka-Ho Wong D, Sum SM, Sablon E, Oi-Lin Ng I, **Lai CL**. Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. Aliment Pharmacol Ther 2005, 22:301-307.

(248) Yuen MF, **Lai CL**. Telbivudine: an upcoming agent for chronic hepatitis B. Expert Rev Anti Infect Ther 2005, 3:489-494.

- (249) Yuan HJ, Yuen MF, Ka-Ho Wong D, Sablon E, **Lai CL**. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat 2005; 12(4):373-379.
- (250) Chong WP, To YF, Ip WK, Yuen MF, Poon TP, Wong WH, **Lai CL**, Lau YL. Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology 2005; 42:1037-1045.
- (251) Tanaka Y, Orito E, Yuen MF, Mukaide M, Sugauchi F, Ito K, Ozasa A, Sakamoto T, Kurbanov F, **Lai CL**, Mizokami M. Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. Hepatol Res. 2005; 33:216-224.
- (252) Sum SS, Wong DK, Yuen JC, **Lai CL**, Yuen MF. Comparison of the COBAS TaqMan HBV test with the COBAS Amplicor monitor test for measurement of hepatitis B virus DNA in serum. J Med Virol. 2005; 77(4): 486-90.
- (253) Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19:91-9.
- (254) Yuen MF, Tanaka Y, Ng IO, Mizokami M, Yuen JC, Wong DK, Yuan HJ, Sum SM, Chan AO, **Lai CL**. Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. J Viral Hepat 2005; 12:513-518.
- (255) Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, **Lai CL**. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 2006; 50:874-879.
- (256) Yuen MF, **Lai CL**. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 2006; 49:96-98.
- (257) **Lai CL**, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L; BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
- (258) Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D; BEHoLD AI463022 Study Group. (**Lai CL**, investigator in the BEHoLD AI463022 Study Group). A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
- (259) Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, Yuen MF, Lai CL, Kramvis A, Kew MC, Smuts HE, Netesov SV, Alter HJ, Mizokami M. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology. 2006; 130:703-714.

- (260) Orito E, Fujiwara K, Tanaka Y, Yuen MF, Lai CL, Kato T, Sugauchi F, Kusakabe A, Sata M, Okanoue T, Niitsuma H, Sakugawa H, Hasegawa I, Mizokami M. A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. Hepatol Res. 2006; 35:127-134.
- (261) Lai CL, Yuen MF. Entecavir: a viewpoint. Drugs. 2006; 66:1623-1624.
- (262) Yuen MF, Tam S, Fung J, Wong DK, Wong BC, **Lai CL**. Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Aliment Pharmacol Ther. 2006; 24:1179-1186.
- (263) Chang TT, **Lai CL**. Hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006; 355:322-323.
- (264) Yuen MF, Lai CL. Recommendations and potential future options in the treatment of hepatitis B. Expert Opin Pharmacother 2006; 7:2225-2231.
- (265) Wong DK, Yuen MF, Ngai VW, Fung J, **Lai CL**. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006; 11:909-916.
- (266) Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAgpositive patients with chronic hepatitis B. Antivir Ther 2006; 11:977-983.
- (267) Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, Wong BC, Lai CL. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther 2006; 11:779-786.
- (268) Tanaka Y, Mukaide M, Orito E, Yuen MF, Ito K, Kurbanov F, Sugauchi F, Asahina Y, Izumi N, Kato M, **Lai CL**, Ueda R, Mizokami M. Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol. 2006; 45:646-653.
- (269) Cheung TK, **Lai CL**, Wong BC, Fung J, Yuen MF. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther 2006; 24:573-583.
- (270) Ito K, Tanaka Y, Orito E, Sugiyama M, Fujiwara K, Sugauchi F, Kato T, Tokita H, Izumi N, Kato M, Yuen MF, **Lai CL**, Gish RG, Ueda R, Mizokami M. T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis. 2006; 42(1):1-7.
- (271) Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol 2006; 45:553-559.
- (272) Yuen MF, **Lai CL**. Response to combined interferon and ribavirin is better in patients infected with hepatitis C virus genotype 6 than genotype 1 in Hong Kong. Intervirology 2006, 49:96-98.

(273) Yuan HJ, Ka-Ho Wong D, Doutreloigne J, Sablon E, Lai CL, Yuen MF. Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. J Infect 2007; 54: 497-503.

- (274) Bourne EJ, Dienstag JL, Lopez VA, Sander TJ, Longlet JM, Hall JG, Kwiatkowski RW, Wright T, **Lai CL**, Condreay LD. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat 2007; 14:55-63.
- (275) Fung J, **Lai CL**, Yuen JCH, Wong DKH, Tanaka Y, Mizokami M, Yuen MF. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antiviral Therapy 2007; 12: 41-46.
- (276) Yuen MF, Wong DKH, Zheng BJ, Chris Chung-Sing Chan, John Chi-Hang Yuen, Benjamin Chun-Yu Wong, **Lai CL**. Difference in T Helper Responses During Hepatitis Flares in HBeAg-positive Patients with Genotypes B and C: Implication for Early HBeAg Seroconversion. Journal of Viral Hepatitis 2007; 14:269-275.
- (277) **Lai CL**, Yuen MF. The natural history and treatment of CHB: critical evaluation of treatment criteria and endpoints. Annals of Internal Medicine 2007; 147:58-61.
- (278) Yuen MF, **Lai CL**. Combination therapy for chronic hepatitis B: simultaneous or sequential? Am J Gastroenterol 2007; 102:105-106.
- (279) Chan HL, Heathcote EJ, Marcellin P, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA; and the 018 Study Group. Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir: A Randomized Trial. Ann Intern Med 2007; 147(11):745-754.
- (280) **Lai CL**, Yuen MF. The natural history of chronic hepatitis B. J Viral Hepat 2007; 14: 6-10.
- (281) Wong DKH, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. Journal of Clinical Microbiology 2007; 45: 3942–3947.
- (282) Lai CL, Gane E, Liaw YF, Hsu CW, Thongawat S, Wang YM, Chen YG, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, DiBisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, for the GLOBE Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
- (283) Yuen MF, Seto WK, Chow DHF, Tsui K, Wong DKH, Ngai VWS, Wong BCY, Fung J, Yuen JCH, **Lai CL**. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Anti Ther 2007; 12(8):1295-303.
- (284) Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, **Lai CL**. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology. 2007; 46:1695-1703.

- (285) Libbrecht E, Doutreloigne J, Van De Velde H, Yuen MF, **Lai CL**, Shapiro F, Sablon E. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 2007; 45:3935-3941.
- (286) Fung J, Yuen MF, Yuen JC, Wong DK, **Lai CL**. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Aliment Pharmacol Ther 2007; 26(3):377-82.
- (287) Fung KT, Fung J, **Lai CL**, Yuen MF. Etiologies of chronic liver diseases in Hong Kong. Eur J Gastroenterol Hepatol 2007; 19:659-664.
- (288) Yuen MF, Lai CL. Hepatitis B virus genotypes: natural history and implications for treatment. Expert Rev Gastroenterol Hepatol 2007; 1:321-328.
- (289) Yuen MF, Tanaka Y, Shinkai N, Poon RT, But DY, Fong DY, Fung J, Wong DK, Yuen JC, Mizokami M, **Lai CL**. Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 2008; 57:98-102.
- (290) Fung KT, Fung J, Lai CL, Yuen MF. Etiologies of Chronic Liver Diseases in Hong Kong. European Journal of Gastroenterology & Hepatology 2007; 19:659-664.
- (291) Schiff E, **Lai CL**, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S; Adefovir Dipivoxil Study 45 Intrnational Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007; 13:349-360.
- (292) Yuen MF, **Lai CL**. Prediction of treatment outcomes for lamivudine. J Gastroenterol Hepatol 2007; 22:964-965.
- (293) Fung J, Lai CL, But D, Wong D, Cheung TK, Yuen MF. Prevalence of Fibrosis and Cirrhosis in Chronic Hepatitis B: Implications for Treatment and Management. Am J Gastroenterol 2008; 103:1421-1426.
- (294) **Lai CL**, Yuen MF. What is the best end point for hepatitis B treatment? Ann Intern Med 2008; 148:560.
- (295) Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int 2008; 28:1408-1416.
- (296) Fung J, **Lai CL**, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2008; 17:1581-1588.
- (297) Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, Yuen MF. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198:808-812.
- (298) Fung J, Lai CL, Yuen MF. New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol. 2008; 23:1182-1192.

- (299) Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, **Lai CL**. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135:1192-1199.
- (300) But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. Vaccine 2008; 26:6587-6591.
- (301) But DY, **Lai CL**, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol. 2008; 14:1652-1656.
- (302) Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, **Lai CL**. HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma. Gastroenterology 2008; 135:1192 1199.
- (303) Hung IF, Poon RT, **Lai CL**, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008; 103:1663-1673.
- (304) Lai CL, Yuen MF. Chronic hepatitis B new goals, new treatment. N Engl J Med. 2008; 359:2488-2491.
- (305) Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, Yuen MF. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008; 198:808-812.
- (306) Fung J, Lai CL, Yuen MF. Drug Profile Telbivudine. Medical Progress. Oct 2008, Vol 35(10)
- (307) Fung J, **Lai CL**, Yuen MF. The importance of HBV DNA monitoring. Virology (Asia Pacific): Issue 1 2008.
- (308) Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY, Chan AOO, Wong BC, Mizokami M, Lai CL. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. Journal of Hepatology 2009; 50:80-88.
- (309) Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV; The GLOBE Study Group. 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B. Gastroenterology 2009; 136:486-495.
- (310) Shouval D, **Lai CL**, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H. Relapse of hepatitis B in HBeAgnegative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50:289-295.
- (311) Yuen MF, Lee SH, Kang HM, Kim CR, Kim J, Ngai V, **Lai CL**. Pharmacokinetics of LB80331 and LB80317 following oral administration of LB80380, a new anti-viral agent for chronic hepatitis B (CHB) in healthy adult subjects, CHB patients, and mice. Antimicrob Agents Chemother 2009; 53(5):1779-1785.
- (312) Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect Dis 2009; 9:256-264.

- (313) Yuen MF, Wong DK, Lai CL. Reply. Gastroenterology 2009; 136: 1843-4.
- (314) Fung J, **Lai CL**, Tanaka Y, Mizokami M, Yuen J, Wong DK, Yuen MF. The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion. Am J Gastroenterol 2009; 104:1940-1946.
- (315) Gish RG, Chang TT, **Lai CL**, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17:16-22.
- (316) Lam ET, Lam CL, Lai CL, Yuen MF, Fong DY. Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection. World J Gastroenterol 2009; 15:3288-3297.
- (317) Lam ET, Lam CL, Lai CL, Yuen MF, Fong DY, So TM. Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes 2009; 7:52.
- (318) **Lai CL**, Yuen MF. The saga of Entecavir. Hepatol Int 2009; 3(3): 421–424.
- (319) Yuen MF, Fung J, Seto WK, Wong DK, Yuen JC, **Lai CL**. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. Antivir Ther 2009; 14:679-85.
- (320) Fung J, Lai CL, Yuen MF. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect 2009; 15:964-70.
- (321) **Lai CL**, Yuen MF. Occult hepatitis B infection: Incidence, detection and clinical implications. ISBT Science Series (An affiliated publication to Vox Sanguinis) 2009; 4:347–51.
- (322) Wu IC, **Lai CL**, Han SH, Han KH, Gordon SC, Chao YC, Tan CK, Sievert W, Tanwandee T, Xu D, Neo BL, Chang TT. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51:1107-9.
- (323) Fung J, Lai CL, Chan SC, But D, Seto WK, Cheng C, Wong DK, Lo CM, Fan ST, Yuen MF. Correlation of Liver Stiffness and Histological Features in Healthy Persons and in Patients With Occult Hepatitis B, Chronic Active Hepatitis B, or Hepatitis B Cirrhosis. Am J Gastroenterol 2010; 105:1116-22.
- (324) Mukaide M, Tanaka Y, Shin-I T, Yuen MF, Kurbanov F, Yokosuka O, Sata M, Karino Y, Yamada G, Sakaguchi K, Orito E, Inoue M, Baqai S, **Lai CL**, Mizokami M. The mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation. Antimicrob Agents Chemother 2010; 54:882-9.
- (325) Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, **Lai CL**, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010; 30:342-55.
- (326) So JC, Hwang YY, Shek WH, Lam CC, **Lai CL**, Kwong YL, El-Omar E. Transfusion-refractory anaemia in liver cirrhosis. Gut 2010; 59(1):5.

(327) Gish RG, Chang TT, **Lai CL**, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17(1):16-22.

- (328) Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010; 51:767-76
- (329) Chang TT, **Lai CL**, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010; 51:422-30.
- (330) Wu IC, **Lai CL**, Han SH, Han KH, Gordon SC, Chao YC, Tan CK, Sievert W, Tanwandee T, Xu D, Neo BL, Chang TT. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51:1185-9.
- (331) Fung J, **Lai CL**, Yuen MF. Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. Expert Rev Anti Infect Ther 2010; 8:717-26.
- (332) Seto WK, **Lai CL**, Fung J, Hung I, Yuen J, Young J, Wong DK, Yuen MF. Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. J Hepatol J Hepatol. 2010 Sep;53(3):444-8.
- (333) Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. J Viral Hepat. 2011; 18:738-44.
- (334) Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52:886-93.
- (335) But DY, Yuen MF, Fung J, **Lai CL**. Safety evaluation of telbivudine. Expert Opin Drug Saf 2010; 9:821-9.
- (336) Yeung P, Wong DKH, Lai CL, Fung J, Seto WK Yuen MF. Profile of Pre-S Deletions in the Natural History of Chronic Hepatitis B Infection. J Med Virol 2010; 82:1843–1849.
- (337) Fung J, Lai CL, But D, Hsu A, Seto WK, Cheng C, Wong DK, Yuen MF. Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. Hepatol Int 2010; 4:716-22.
- (338) Yuen MF, Lee CK, Wong DK, Fung J, Hung I, Hsu A, But DY, Cheung TK, Chan P, Yuen JC, Fung FK, Seto WK, Lin CK, **Lai CL**. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut. 2010; 59:1389-93.

(339) **Lai CL**, Yuen MF. Systemic corticosteroid and reactivation of chronic hepatitis B. Respirology. 2010; 15:1017-8.

- (340) Seto WK, **Lai CL**, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol. 2011; 55:522-8.
- (341) Fung J, **Lai CL**, Cheng C, Wu R, Wong DK, Yuen MF. Mild-to-Moderate Elevation of Alanine Aminotransferase Increases Liver Stiffness Measurement by Transient Elastography in Patients With Chronic Hepatitis B. Am J Gastroenterol 2011; 106:492-6.
- (342) Lai CL, Yuen MF. Management of Chronic Hepatitis B. Chen C-W, Cheng J, Ginès P, Ouyang Q, Schölmerich J (eds): Gut and Liver. Falk Symposium 174. Basel, Karger, 2011, pp 95–101.
- (343) Yeung P, Wong DK, **Lai CL**, Fung J, Seto WK, Yuen MF. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 2011; 203:646-54.
- (344) Yuen MF, Ka-Ho Wong D, Lee CK, Tanaka Y, Allain JP, Fung J, Leung J, Lin CK, Sugiyama M, Sugauchi F, Mizokami M, **Lai CL**. Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection. Clin Infect Dis. 2011; 52:624-32.
- (345) Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol 2011; Suppl 1:138-43.
- (346) Fung J, Lai CL, Yuen MF. To stop or not to stop: The quest for long-term viral suppression. J Gastroenterol Hepatol 2011; 26:420-2.
- (347) Fung J, Seto WK, Lai CL, Yuen J, Wong DK, Yuen MF. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. J Hepatol. 2011; 54:195-200.
- (348) Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, **Lai CL**. Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. Am J Gastroenterol. 2011 Jul;106(7):1264-71.
- (349) Fung J, Lai CL, Yuen J, Cheng C, Wu R, Wong DK, Seto WK, Hung IF, Yuen MF. Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: outcome at 2 Years. Hepatology 2011; 53:1148-53.
- (350) Seto WK, Tanaka Y, Liu K, **Lai CL**, Yuen MF. The Effects of IL-28B and ITPA Polymorphisms on Treatment of Hepatitis C Virus Genotype 6. Am J Gastroenterol 2011; 106:1007-8.
- (351) Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepat 2011; 18:e200-5.
- (352) Seto WK, Ng M, Chan P, Ng IO, Cheung SC, Hung IF, Yuen MF, Lai CL. Ketamine-induced cholangiopathy: a case report. Am J Gastroenterol 2011; 106:1004-5.

- (353) Hsu A, **Lai CL**, Yuen MF. Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. Curr Hepat Rep 2011; 10:106-111.
- (354) Seto WK, Yuen MF, Fung J, Lai CL. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int 2011 Jun 19. [Epub ahead of print]
- (355) Fung J, Lai CL, Seto WK, Yuen MF. The use of transient elastography in the management of chronic hepatitis B. Hepatol Int 2011 Jun 22. [Epub ahead of print].
- (356) Seto WK, Lee CF, **Lai CL**, Ip PP, Fong DY, Fung J, Wong DK, Yuen MF. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 2011;6(8):e23077.
- (357) Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF. Stability of hepatitis B surface antigen over time: implications for studies using stored sera. J Med Virol 2011; 83:1900-4.
- (358) Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, **Lai CL**, Lo CM. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141:1212-9.
- (359) Wong DK, Huang FY, **Lai CL**, Poon RT, Seto WK, Fung J, Hung IF, Yuen MF. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54:829-36.
- (360) Chan K, Yam I, Yuen J, Yuen MF, **Lai CL**, Alexander GJ, Chan TK, Chan V. A comprehensive HBV array for the detection of HBV mutants and genotype. Clin Biochem 2011; 44:1253-60.
- (361) Fung J, **Lai CL**, Young J, Wong DK, Yuen J, Seto WK, Yuen MF. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol 2011; 106:1766-73.
- (362) Tung EK, Mak CK, Fatima S, Lo RC, Zhao H, Zhang C, Dai H, Poon RT, Yuen MF, Lai CL, Li JJ, Luk JM, Ng IO. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int 2011; 31:1494-504.
- (363) Fung J, **Lai CL**, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011; 66:2715-25.
- (364) Lam YF, Yuen MF, Seto WK, **Lai CL**. Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep 2011; 10:235-243.
- (365) Huang JQ, Zheng GF, Lai CL, Yuen MF, Wong BC. Risk of liver cancer in patients with hepatitis B or C. Hong Kong Med J 2011; 17 Suppl 6:41-3.
- (366) Chan KYY, Wong CM, Kwan JSH, Lee JMF, Cheung KW, Yuen MF, **Lai CL**, Poon RTP, Sham PC, Ng IOL. Genome-wide association study of hepatocellular carcinoma in southern Chinese patients with chronic hepatitis B virus infection. PLoS ONE 2011; 6(12):e28798.

- (367) Seto WK, **Lai CL**, Yuen MF. Nucleic Acid testing for the detection of HBV DNA. Hepat Mon 2011;11:847-8.
- (368) Seto WK, Lai CL, Ip PP, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS One 2012;7(2):e32622.
- (369) Seto WK, Wong DK, Fung J, Hung IF, Fong DY, Yuen JC, Tong T, **Lai CL**, Yuen MF. A large case-control study on the predictability of hepatitis B surface antigen (HBsAg) levels three years before HBsAg seroclearance. Hepatology 2012 Mar 15. [Epub ahead of print]
- (370) Pan CQ, Tong M, Kowdley KV, Hu KQ, Chang TT, **Lai CL**, Yoon SK, Lee SS, Cohen D, Tang H, Tsai N. High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. Clin Gastroenterol Hepatol 2012 Apr 1. [Epub ahead of print]
- (371) Seto WK, **Lai CL**, Yuen MF. Acute-on-chronic liver failure in chronic hepatitis B. J Gastroenterol Hepatol 2012; 27:662-9.

International papers on gastroenterology and other subjects

- (372) Lam SK, Lai CL. Inhibition of sulphiride on the cephalic phase of gastric acid and gastrin secretion in duodenal ulcer patients. Scandinavian Journal of Gastroenterology 1976; 11:27-31.
- (373) Lam SK, Lai CL. Effect of sulphiride on the cephalic phase of gastric acid and gastrin secretion on duodenal ulcer patients. Proceedings of the 5th Asian Pacific Congress of Gastroenterology, Singapore, May 23-27th 1976.
- (374) Prescott J, Sircus W, **Lai CL**, Lam SK. Failure to confirm evidence for existence of two populations with duodenal ulcer. British Medical Journal 1976; 2:677.
- (375) Ferguson A, **Lai CL**, Denton-Miller P. Coeliac disease objectives of life-long follow-up. Health Bulletin (Scotland), March 1977, 78-80.
- (376) Lam SK, Lai CL. Gastric ulcers with and without associated duodenal ulcer have different pathophysiology. Clinical Science and Molecular Medicine 1978; 55:97-102.
- (377) Lam SK, Lam KC, **Lai CL**, Yeung CK, Yam LYC, Wong WS. Treatment of duodenal ulcer with antacid and sulphiride, a double-blind controlled study. Gastroenterology 1979; 76:315-22.
- (378) Lee PK, **Lai CL**, Lok ASF, Tse TF, Lai KN, Chow SF, Lam KC. Haemodynamic responses to intravenous cimetidine in subjects with normal lung functions and in subjects with chronic airway obstruction. British Journal of Clinical Pharmacology 1981; 11:339-43.
- (379) Wang C, **Lai CL**, Lam KC, Yeung KK. Effect of cimetidine on gonadal function in an man. British Journal of Clinical Pharmacology 1982; 13:791-4.

(380) Chow JSF, Wang RYC, Wong PHC, Chen WWC, **Lai CL**. Intravenous ranitidine has no haemodynamic effects in subjects with normal lung function and patients with chronic obstructive airway disease. Australian and New Zealand Journal of Medicine 1983; 13:261-3.

29

- (381) Wang C, Wong KL, Lam KC, Lai CL. Ranitidine does not affect gonadal function in man. British Journal of Clinical Pharmacology 1983; 16:430-2.
- (382) Chan CW, Lam KC, Ho JCI, **Lai CL**. rohn's syndrome in Chinese. American Journal of Proctology, Gastroenterology and Colon and Rectal Surgery 1984; 8-17.
- (383) Lai CL, Wu PC, Lin HJ, Wong KL. Case report of symptomatic porphyria cutaneous tarda associated with histiocytic lymphoma. Cancer 1984; 53; 3:573-6.
- (384) Yeung CK, Wong KL, Ng MT, **Lai CL**. A randomized trial of the effects of cimetidine, ranitidine and antacids on renal functions in patients with duodenal ulcers. Journal of Clinical Therapeutics 1984; 6:620-4.
- (385) Lai CL, Wu PC, Wong KL, Lok ASF. Clinical features of ulcerative proctocolitis in Hong Kong Chinese: a review of three decades, American Journal of Proctology and Gastroenterology and Colon and Rectal Surgery 1985; 36: 14-9.
- (386) Lam SK, Lai CL, Lee LNW, Fok KH, Ng MMT, Siu KF. Factors influencing the healing of duodenal ulcer control of nocturnal secretion by H2-blockade and characteristics of patients who failed to heal. Digestive Diseases and Sciences 1985; 30:45-51.
- (387) Lam SK, Lau WY, **Lai CL**, Lee NW, Hui WM, Lok A, Ng M, Fok KH, Yu HC. Efficacy of sucralfate in corpus, prepyloric and duodenal-ulcer associated gastric ulcers a double-blind placebo controlled study. American Journal of Medicine 1985; 79 (Suppl 2C):24-31.
- (388) Lam SK, Lai CL, Ng M, Fok KH, Hui WM. Duodenal ulcer healing by separate reduction of postprandial and nocturnal acid secretion have different pathophysiology. Gut 1985; 26:1038-44.
- (389) Wu PC, Pang SW, Chan KW, **Lai CL**. Statistical and pathological analysis of oral tumours in Hong Kong Chinese. Journal of Oral Pathology 1985; 15:98-102.
- (390) Hui WM, Lam SK, Ho J, Ng MMT, Lui I, Lai CL, Lok ASF, Lau WY, Poon GP, Choi S, Choi TK. Chronic antral gastritis in duodenal ulcer natural ulcer and treatment with prostaglandin E. Gastroenterology 1986; 91:1095-101.
- (391) Lam SK, Hui WM, Lau WY, Branicki FJ, **Lai CL**, Lok ASF, MMT Ng, Fok PJ, Poon GP, Choi TK. Cigarette smoking affects healing and relapse of cimetidine- treated but not sucralfate-treated duodenal ulcer. Gastroenterology 1987; 92:1193-201.
- (392) Hui WM, Lam SK, Chau PY, Ho J, Lau WY, Poon KP, **Lai CL**, Lok ASF, Lui IOL, Ng MMT. Pathogenetic role of campylobacter pyloridis in gastric ulcer. Journal of Gastroenterology and Hepatology 1987; 2:309-16.
- (393) Hui WM, Lam SK, Chau PY, Ho J, Lui I, **Lai CL**, Lok ASF, Ng MMT.Persistence of campylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Journal of Digestive Diseases & Sciences 1987; 32, 11:1255-60.

(394) Lam SK, Branicki FJ, **Lai CL**, Lok ASF, Choi TK, Hui WM, Lau WY, Ng MMT, Fok PJ, Poon GP. Sucralfate overcomes adverse effect of cigarette smoking on duodenal ulcer healing and prolongs subsequent remission. Gastroenterology 1987; 92:1193-201.

- (395) Lam SK, Choi TK, **Lai CL**, Lok ASF, Lau WY, Hui WM, Choi S, Poon GP. Healing of duodenal ulcer by misoprostol is unaffected by smoking. Postgraduate Medical Journal 1988; 64(Supp. 1):81.
- (396) Chung HT, Wong KL, Liang RHS, Loke SL, Liu HW, Tso WK, Chan SCH, Lai KSL, Lai CL. Non-Hodgkin's lymphoma as a cause of hypoadrenalism. Australian and New Zealand Journal of Medicine 1987; 17:605-7.
- (397) Leung MP, Chau KT, Hui TW, Tam AYC, Chan FL, **Lai CL**, Yeung CY. Necrotizing enterocolitis in neonates with symptomatic congenital heart disease. Journal of Paediatrics 1988; 113: 1044-6.
- (398) Hui WM, Lam SK, Ho J, Ng I, Lau WY, Branicki FJ, **Lai CL**, Lok ASF, Ng MMT, Fok PJ, Poon GP, Choi TK.The effect of sucralfate and cimetidine in duodenal ulcer associated antral gastritis and campylobacter pylori. American Journal of Medicine 1989; 86 Supp(GA):60-5.
- (399) Hui WM, Lam SK, Lau WY, Branicki FJ, Lok ASF, Ng MMT, **Lai CL**, Poon GP. Omeprazole and ranitidine in duodenal ulcer healing and subsequent relapse a randomized double-blind study with weekly endoscopic assessment. Journal of Gastroenterology and Hepatology 1989; 4:35-43.
- (400) Lin CK, Liu HW, Tse PWT, **Lai CL**, Chan GT. A patient with large granular lymphocytosis of unusual phenotype and polymorphic T-cell resector beta-chain gene rearrangement. American Journal of Clinical Pathology 1990; 94:211-61.
- (401) Lam SK, Hui WM, Ng MMT, Lok ASF, **Lai CL**, Branicki FJ, Lau WY, Poon GP. Reduced meal-stimulated acid secretion versus reduced nocturnal acid secretion for the healing of duodenal ulcer. Journal of Digestive Disease and Sciences 1989; 34:1494-500.
- (402) Hui WM, MMT Ng, A Lok, SK Lam, Lai CL, YN Lau. A randomized study of laser photocoagulation, heater probe and bipolar electrocoagulation in the treatment of actively bleeding ulcer. Gastrointestinal Endoscopy 1991; 37:299-304.
- (403) Hui WM, Lam SK, Ho J, **Lai CL**, Lok AS, Ng MM, Lau WY, Branicki FJ. Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Digestive Diseases and Science 1991; 36:577-582.
- (404) Chin KP, Lok ASF, Wong LSK, **Lai CL**, Wu PC. Current seroepidemiology of hepatitis A in Hong Kong. Journal of Medical Virology 1991; 34: 191-3.
- (405) Lok ASF, Ma OCK, Chan TM, **Lai CL**, Chung HT, Ng CPL, Lam JSC. Overestimation of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera. Hepatology 1991; 14: 756-62.
- (406) Hui WM, Lam SK, Lok ASF, Ng MMT, **Lai CL**. Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment. American Journal of Medicine 1992; 92: 265-74.

- (407) Lai KC, Yuen ST, Ching CK, Hu HC, Wong YW, **Lai CL**, Lam SK. Tuberculosis of the common bile duct. Illustrated Case Reports in Gastroenterology 1994; 1, 1-8.
- (408) Ching CK, Leung KP, Yung RWH, Lam SK, Wong BCY, Lai KC, Lai CL. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 1996; 38: 675-8.
- (409) Lam SK, Ching CK, Lai KC, Wong BC, **Lai CL**, Chan CK, Ong L. Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. Gut 1997; 41(1):43-8.
- (410) Wong BC, Lam SK, Lai KC, Hu-WH, Ching CK, Ho J, Yuen ST, Chan CK, Lau GK, **Lai CL**. Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. Aliment Pharmacol Ther 1999; 13(3):303-9.
- (411) Wong BCY, Wong WM, Tang VSY, Lai KC, Yuen ST, Hu WHC, Chan CK, Lau GKK, **Lai CL**, Lam SK. An evaluation of whole blood testing for Helicobacter pylori infection in the Chinese population. Aliment Pharmacol Ther 2000; 14:331-335.
- (412) Mok CC, Wong WM, Shek TW, Ho CT, Lau CS, Lai CL. Cumulative hepatotoxicity induced by continuous low-dose cyclophosphamide therapy. American Journal of Gastroenterology 2000; 95(3):845-846.
- (413) Wong WM, Wong BCY, Wong KW, Fung FMY, Lai KC, Hu WH, Yuen ST, Leung SY, Lau GKK, **Lai CL**, Chan CK, Go R, Lam SK. 13C-urea breath test without a test meal is highly accurate for the detection of helicobacter pylori infection in Chinese. Aliment Pharmacol Ther 2000; 14(10):1353-1358.
- (414) Wong BCY, Chan CK, Wong KW, Wong WM, Yuen MF, Lai KC, Hu WH, Lau GKK, **Lai CL**, Lam SK. Evaluation of a new referral system for the management of dyspepsia in Hong Kong: role of open-access upper endoscopy. J Gastroenterol Hepatol 2000; 15(11):1251-1256.
- (415) Chan AOO, Lam SK, Chu KM, Lam CM, Kwok E, Leung SY, Yuen ST, Hui WM, Lai KC, Wong CY, Hu HC, **Lai CL**. Soluble E-Cadherin is a good prognostic marker in gastric carcinoma. Gut 2001; 48(6):808-811.
- (416) Hui CK, Lai KC, Yuen MF, Ng M, **Lai CL**, Lam SK. Acute cholangitis predictive factors for emergency ERCP. Aliment Pharmacol Ther 2001; 15:1633-1637.
- (417) Hui CK, Lai KC, Yuen MF, Wong WM, Lam SK, **Lai CL**. Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding? Alimentary Pharmacology & Therapeutics 2002; 16(5):929-936.
- (418) Hui CK, Lai KC, Yuen MF, Ng MNT, Lam SK, Lai CL. Role of cholecystectomy in preventing recurrent acute cholangitis. Gastrointestinal Endoscopy 2002; 56(1):55-60.
- (419) Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO, **Lai CL**, Wong J. Lansoprazole prevention of recurrent ulcer complications associated with long term low-dose aspirin use after helicobacter pylori eradication. The New England Journal of Medicine 2002; 346(26):2033-2038.
- (420) Hui CK, Lai KC, Wong WM, Yuen MF, Lam SK, **Lai CL**. A randomised controlled trial of endoscopic sphincterotomy in acute cholangitis without common bile duct stones. Gut 2002; 51(2):245-247.

- (421) Hui CK, Lai KC, Ng M, Wong WM, Yuen MF, Lam SK, **Lai CL**, Wong BC. Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. Aliment Pharmacol Ther 2003; 17:289-296.
- (422) Hui CK, Lai KC, Yuen MF, Ng M, Chan CK, Hu W, Wong WM, Lai CL, Wong BC. Does the addition of endoscopic sphincterotomy to stent insertion improve drainage of the bile duct in acute suppurative cholangitis? Gastrointest Endosc 2003;58(4):500-504.
- (423) Hui CK, Lai KC, Wong WM, Yuen MF, Ng M, Chan CK, Hu W, Cheung WW, Lai CL, Wong BC. Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: six-hour versus overnight observation. J Gastroenterol Hepatol 2004; 19:1163-8.
- (424) Wong WM, Lai KC, Yiu WC, Wong BC, Chan FL, **Lai CL**. Intestinal tuberculosis mimicking fistulizing Crohn's disease. J Gastroenterol Hepatol 2007; 22:137-139.
- (425) Mak CM, Lam CW, Tam S, **Lai CL**, Chan LY, Fan ST, Lau YL, Lai JY, Yuen P, Hui J, Fu CC, Wong KS, Mak WL, Tze K, Tong SF, Lau A, Leung N, Hui A, Cheung KM, Ko CH, Chan YK, Ma O, Chau TN, Chiu A, Chan YW. Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: Identification of 17 novel mutations and its genetic heterogeneity. J Hum Genet 2008; 53:55-63.
- (426) Seto WK, Mak CM, But D, Hung I, Lam CW, Tam S, Yuen MF, **Lai CL**. Mutational analysis for Wilson's disease. Lancet 2009; 374:662.

Books

- (1) Co-editor (with Lam SK & Yeoh EK) of "Viral Hepatitis B Infection in the Western Pacific Region: Vaccine and Control". Singapore World Scientific Publications Co., 1984.
- (2) MD Thesis: Chronic Hepatitis B-Related Liver Diseases in the Chinese, 1994.
- (3) Co-editor with Locarnini S, "Hepatitis B Virus", Human Virus Guides, International Medical Press, February 2003.
- (4) Co-editor with Locarnini S, "Hepatitis B Virus", Human Virus Guides, International Medical Press, 2nd Edition, October 2008.

Book Chapters

- (1) **Lai CL** and Yuen MF. Clinical experience and follow-up with lamivudine in the Asian population. Ed. by RF Schinazi, C Rise and J-P Sommadossi. In: Frontiers in Viral Hepatitis. Elsevier Science 2002; 383-390.
- (2) Yuen MF and Lai CL. Design for Clinical Trials in Far East. In: Lau JYN et. HBV Protocol 2002.
- (3) **Lai CL**. "Discovery of human hepatitis B virus". In Lai & Locarnini ed, "Hepatitis B Virus", International Medical Press, February 2003.
- (4) **Lai CL**, Yuen MF, Locarinini S. "Treatment of Chronic Hepatitis B". In Lai & Locarnini. 1st ed, "Hepatitis B Virus Guide", International Medical Press, February 2003.

(5) **Lai CL**, Yuen MF. "Treatment of HBeAg-positive chronic hepatitis B patients". In: Arroyo V, Navasa M, Forns X, Bataller R, Sánchez-Fueyo A, Rodés J ed. Update in Treatment of Liver Disease, pp 227-233, 2005, Ars Medica, Barcelona, Spain.

33

- (6) Lai CL, Chen DS, Wong BCY, Yuen MF. In: Lau CP, Chen MZ, Kumana CR, Lai CL, Lai KN, Lam KSL, Lam WK ed. Gastroenterology and Hepatology. Problem-Based Medical Cases Management, p 75 107, 2005. Hong Kong University Press.
- (7) Yuen MF and Lai CL. L-Thymidine and related compounds. In: Schinazi, Rice and Sommadossi ed. Framing the knowledge of viral hepatitis. 2005.
- (8) Yuen MF, **Lai CL**. HBsAg Seroclearance in the Natural History of Chronic HBV Infection. In: Emmet B. Keeffe ed. Current Hepatitis Reports, Volume 4, Issue 4, 2005.
- (9) Yuen MF, **Lai CL**. "Chemotherapy and Radiotherapy Treatments for Primary Hepatoma" in the book of "Gastro-intestinal Oncology: Evidence and Analysis. In preparation, 2005.
- (10) Fung J, **Lai CL**, Yuen MF. Telbivudine: a new treatment option in the management of chronic hepatitis B. Hepatitis B Annual 2006: Vol 3: 14-34.
- (11) Chan P, Yuen MF, **Lai CL**. Chemotherapy and radiotherapy for the treatment of hepatocellular carcinoma. In McCulloch P ed. Gastrointestinal Oncology: Evidence and analysis 2007.
- (12) Fung J, **Lai CL**, Yuen MF. Treatment of chronic hepatitis C with different genotypes. In Jirillo E ed. The use of interferons in hepatitis C disease: from biology to clinical application. Springer-Link, 2008, pp 130-147.
- (13) **Lai CL**. A man with worsening jaundice and confusion. In Mark Strachan, Surendra Sharma and John Hunter ed. Davidson's Clinical Cases. Elsevier Ltd., Edinburgh, 2008, Chap 64, pp 222-224.
- (14) Yuen MF and **Lai CL**. Natural history of chronic hepatitis B infection. *In* Lai CL and Locarnini S (ed.), Hepatitis B Virus, 2nd Edition, International Medical Press, October 2008.
- (15) **Lai CL**, Yuen MF, Locarinini S. "Treatment of Chronic Hepatitis B Infection". *In* Lai CL and Locarnini S (ed.), Hepatitis B Virus, 2nd Edition, International Medical Press, October 2008.
- (16) **Lai CL** and Wong DKH, Discovery and Classification, *In* Lai CL and Locarnini S (ed.), Hepatitis B Virus, 2nd Edition, International Medical Press, October 2008.
- (17) **Lai CL**. A man with worsening jaundice and confusion. In Mark Strachan, Surendra Sharma and John Hunter ed. Davidson's 100 Clinical Cases. Elsevier Ltd., Edinburgh, 2010 (under revision).

Public and invited lectures

- (1) "A Review of Hepatocellular Carcinoma", Oncology Training Course, Farmitalia Carlo Erba, Manila, 1983.
- (2) The Ambuj Nath Bose Lecture entitled "Chronic Hepatitis B Related Diseases in Hong Kong", Annual Meeting, the Royal College of Physicians of Edinburgh, Hong Kong, January 1985.
- (3) "Hepatoma: Therapeutic Achievements The Dawn of a New Era?", International Conference on Cancer Therapy Trials, Melbourne, Australia, March 1985.
- (4) "Chronic Hepatitis B Diseases", the Satellite Symposium of the Royal Australasian College of Physicians, September 1985.
- (5) "Hepatitis B Carriers in Hong Kong", Seminar on Recent Developments in Hepatitis B, Kuala Lumpur, Malaysia, April 1986.
- (6) "The Spectrum of Hepatitis B Diseases", the University of Washington, Seattle, USA, November 1986.
- (7) "The Clinical and Therapeutic Aspects of Hepatitis B Diseases", the Good Samaritan Medical Center Far East Medical Symposium, December 1986.
- (8) "Chronic Hepatitis Diseases and Hepatoma", the Friendship Hospital of Beijing, People's Republic of China, January 1986.
- (9) "Hepatitis B Diseases and Hepatocellular Carcinoma", Guangzhou Medical College, Guangzhou, China, June 1986.
- (10) "Natural History of HB-Chronic Active Liver Disease"; and "Use of Recombinant DNA Hepatitis B Vaccine in Children", the International Meeting on Gastroenterology, Portuguese Society of Gastroenterology, December 1986.
- (11) "Adriamycin versus Recombinant Interferon in the Treatment of Hepatocellular Carcinoma", International Symposium on the Immunology of the Gastrointestinal Tract and the Liver, Jerusalem, Israel, March 1987.
- (12) Multiple lectures on hepatitis B related disease in China, the Third National Conference of Chinese Society of Digestive Diseases, Kunming, Yunnan, November 1987.
- (13) The Annual Teehankee Memorial Lecture "Chronic Hepatitis B Related Disease", Manila, Philippines, November 1987.
- (14) Hepatitis B Virus: Treatment of Chronic Carriers and the Possibilities of its Global Irradiation", Eleventh Annual Convention of the Philippine Society for Microbiology and Infectious Diseases, Manila, Philippines, December 2, 1988.
- (15) "Medical Therapy of Hepatocellular Carcinoma", the International Cancer Conference, Hong Kong, November 1994.

- (16) "Primary Liver Cancer", Second EORTC International Symposium, Hong Kong, February 1995.
- (17) "Chronic Hepatitis", Fourtheenth WONCA World Conference, Hong Kong, June 1995.
- (18) "The Prognostic Implications of Hepatitis B and C", Eighteenth International Congress of Life Assurance Medicine, Washington, September 1995.
- (19) Drug Evaluation Committee Meeting for Lamivudine, Beijing, January 27, 1996.
- (20) The Third Shanghai Symposium on Liver Cancer & Hepatitis, Shanghai, China, March 5-7, 1996.
- (21) Falk Symposium No.92 "Update on Hepatobiliary Diseases 1996", Hong Kong, Feb 29 Mar 1, 1996.
- (22) "Management of Chronic Hepatitis B in Asia", the Seventh International Congress for Infectious Diseases, Hong Kong, June 1996.
- (23) "Cost-effectivenss of Vaccination against Hepatitis A in Areas of Intermediate Endemicity", 7th International Congress for Infectious Diseases, Hong Kong, June 1996.
- (24) Eighth Overseas Meeting of the Royal College of Surgeons of Edinburgh Jointly with the College of Surgeons of Hong Kong, October 27-30, 1996.
- (25) Antiviral Therapy for Chronic Hepatitis B", the Eighth National Viral Hepatitis Meeting of China, Wuhan, China, November 15-18, 1996.
- (26) "Lamivudine in Chronic Hepatitis B", Joint Meeting of the Royal Australasian College of Physicians and Hong Kong College of Physicians, Hong Kong, December 8-9, Hong Kong.
- (27) "Chronic Hepatitis B Carriage: Public Health Aspects"; and "Monitoring Progression an Outcome of Therapy for chronic Hepatitis B", the Asia-Pacific Hepatitis B Public Health Strategy Board Meeting, Singapore, January 20-21, 1997.
- (28) "Viral Hepatitis Treatment Strategies in the 21st Century", GP Symposium: GI Disease in the New Millennium, the New Singapore Changi Hospital (a large restructured governmental hospital), Singapore, July 5, 1997.
- (29) "New Perspectives in the Management of Chronic Hepatitis B", Gastroenterological Society of Singapore, Singapore, December 2, 1997.
- (30) "Long Term Benefit of a Novel Antiviral Therapy in Chronic Hepatitis B", Symposium Advances in the Management of Hepatitis B, Alimentary Disease Week Hong Kong, December 16, 1997.
- (31) "New Perspectives in the Treatment of Chronic Hepatitis B", the Second Annual Scientific Meeting of The Hong Kong Society for Infectious Diseases, March 14, 1998.

- (32) "Antiviral Therapy for Chronic Hepatitis B and C in Asians", the First Annual Stanford Asia Liver Symposium, March 15, 1998.
- (33) "Lamivudine in Chinese with Chronic Hepatitis B", the 1st Scientific Meeting of the Cheng Si Yuan (China-International) Hepatitis Research Foundation, Shenzhen, China, August 15-16, 1998.
- (34) "New Perspectives in the Treatment of Chronic Hepatitis B", the 1998 Autumn Convention of the Gastroenterological Society of Taiwan, Taiwan, October 3-4, 1998.
- (35) "New Antiviral Therapies for Chronic Hepatitis B", the scientific meeting of the Korean Association of the Study of the Liver, Seoul, Korea, November 19, 1998.
- (36) "Carcinoma of Liver: An Overview", the 1st International Congress of Hong Kong Academy of Medicine, November 26-29, 1998.
- (37) "New Perspectives in the Treatment of Chronic Hepatitis B", the Meeting on Gastroenterology, Centro Hospitalar Conde De Sáo Januário, Macau, December 12-13, 1998.
- (38) "Lamivudine Screening and Selection of Patients for Treatment"; and "Lamivudine Resistance, its Clinical Relevance and Management", the Asian-Pacific Hepatitis B Public Health Strategy Board Meeting, Singapore, December 7-8, 1998.
- (39) "Hepatitis B", the Academy of Insurance Medicine of Asia-II theld in Bangkok, Thailand, March 8-10, 1999.
- (40) "Lamivudine: Current Status and YMDD Variant HBV", Hong Kong Association for the Study of Liver Diseases Symposium 'Treatment Advancement in Chronic Hepatitis B Therapy', Sheraton Hotel, Hong Kong, March 29, 1999.
- (41) "Viral replication profound suppression with lamivudine", the International Launch Symposium of Zeffix a major therapeutic advance in chronic hepatitis B held by GlaxoWellcome, Hong Kong Convention Centre, Hong Kong, July 9-10, 1999.
- (42) "Natural History of Persistent HBV Infection", the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy held in San Francisco, California, USA, September 6-29, 1999.
- (43) "Use of Lamivudine in Liver Transplantation", the Annual Scientific Meeting of the Area of Distinction Liver Diseases, the University of Hong Kong, Hong Kong, November 20-21, 1999.
- (44) "Clinical Experience and Follow Up with Lamivudine in the Asian Population", the Third International Conference on Therapies for Viral Hepatitis, Maui, Hawaii, 12-16 December 1999.
- (45) "Use of Lamivudine in the Treatment of Asymptomatic Hepatitis B Disease and in Hepatitis B Liver Transplant", the Asian Pacific Association for the Study of Liver and the Academy of Medicine, Singapore, February 16-19, 2000.
- (46) "Lamivudine Past, Present and Future", the Eleventh Asian Pacific Congress of Gastroenterology and Eighth Asian Pacific Congress of Digestive Endoscopy, Hong Kong, March 10-14, 2000.

- (47) "Experience with lamivudine in Asian trials", the Tenth International Symposium on Viral Hepatitis and Liver Disease, Atlanta, GA, USA, April 9-13, 2000.
- (48) "Current Management of Chronic Hepatitis B Virus Infection", the Fourth World Congress of the International Hepato-Pancreato-Biliary Association, Brisbane, Australia, May 31, 2000.
- (49) "Clinical Profile of Lamivudine", the IASL/APASL Joint Meeting 2000 "A Major Therapeutic Advance in Chronic Hepatitis B", Fukuoka, Japan, June 2-7, 2000.
- (50) "Anti-tuberculous Drugs and the Liver", the Hong Kong Medical Forum 2000, Department of Medicine, The University of Hong Kong, July 1-2, 2000.
- (51) "Hepatitis" to public, the Cancer Centre, Queen Mary Hospital, Hong Kong, July 6, 2000.
- (52) "Lamivudine 4-year Clinical Study Data", a major therapeutic advance in chronic hepatitis B meeting, Vietnam, July 4, 2000.
- (53) "New Era in Hepatitis B Management", the National Congress of the Indonesian Society of Internal Medicine, Surabaya, Indonesia, July 7-11, 2000.
- (54) "Newer Modalities for the Treatment of Hepatocellular Carcinoma", the Second National Single Theme Symposium on "Hepatitis B Infection in India Therapeutic Options and Prevention Strategies", New Delhi, India, September 2-3, 2000.
- (55) "Mechanisms and Treatment Options for Lamivudine Resistance", the Second National Single Theme Symposium 'Hepatitis B Infection in India Therapeutic Options and Prevention Strategies', New Delhi, India, September 2-3, 2000.
- (56) "Hepatitis", Hong Kong College of Family Physicians, Hong Kong Exhibition & Convention Centre, Hong Kong, September 16, 2000.
- (57) "Therapy of Hepatitis B Infection", the Liver Diseases in the New Millennium [Fourth Shanghai International Symposium on Liver Cancer and Hepatitis and Second Scientific Meeting of Cheng Si-yuan (China-International) Hepatitis Research Foundation), Shanghai, China, September 23-26, 2000.
- (58) "Hepatitis B Infection and Treatment", the Joint Scientific Meeting of the Hong Kong College of Physicians, Federation of the Royal Colleges of Physicians of the UK, Singapore Academy of Medicine and the Hong Kong College of Paediatricians, Hong Kong, October 14-15, 2000.
- (59) "Treatment Strategies for Managing Chronic Hepatitis B", Annual Meeting of American Association for the Study of Liver Diseases, Dallas, Texas, 28 October 2000.
- (60) "Lamivudine", Dhaka, Bangladesh on November 10, 2000.
- (61) "Hepatitis trials", Drug Information Association Meeting, Hong Kong, November 16-19 2000.
- (62) "Chronic Hepatitis B and Acute Pancreatitis", International Symposium on Hepatology 2000 (Thirteenth Annual Scientific Meeting of the Hong Kong Association for the Study of Liver Diseases), Hong Kong, November 17-18, 2000.

- (63) "A New Look at Viral Hepatitis", the Seventh Western Pacific Congress on Chemotherapy and Infectious Diseases, Hong Kong, December 12, 2000.
- (64) "Natural History of Hepatitis B", Forum on Hepatitis B in Asia, Hong Kong, January 16, 2001.
- (65) "Acute & Chronic Viral Hepatitis A-G" for the nursing staff of Hong Kong Red Cross Blood Transfusion Services, Hong Kong, February 3, 2001.
- (66) "Transcatheter Intra-arterial Interferon Embolisation for the Treatment of Hepatocellular Carcinoma", the Second Annual Scientific Meeting of the Centre for the Study of Liver Disease (CSLD), Hong Kong, February 17-18, 2001.
- (67) "Acute & Chronic Viral Hepatitis A-G", Department of Health, Hong Kong, March 21, 2001.
- (68) "A Phase 2 Dose-ranging Study of Oral Entecavir vs Lamivudine in Adults with Chronic Hepatitis B", the Thirty-sixth Annual Meeting of the European Association for the Study of the Liver, Prague, Czech Republic, April 22, 2001.
- (69) "Clinical Experiences of Lamivudine in the Asian Region", the GlaxoSmithKline Satellite Symposium, the Thirty-seventh Annual Meeting of the Japan Society of Hepatology, Yokohama, Japan, May 17-18, 2001.
- (70) "Clinical Experiences of Lamivudine in the Asian Region", the University Health Services, The University of Hong Kong, Hong Kong, May 25, 2001.
- (71) "Treatment of Chronic Hepatitis B", Bristol-Myers Squibb Company Infectious Disease Selection Committee Meeting, Newport, Rhode Island, USA, June 21-24, 2001.
- (72) "Recent Research on the Treatment of Chronic Hepatitis B", the Sixth Hong Kong Medical Forum, Department of Medicine, Faculty of Medicine, The University of Hong Kong, Hong Kong Convention & Exhibition Centre, Hong Kong, July 7-8, 2001.
- (73) "Interferon Treatment for Inoperable Hepatocellular Carcinoma", Shanghai, China, October 27, 2001.
- (74) "HCV Assessing The Risk Of Cirrhosis And Hepatocellular Carcinoma", the Fourth Scientific Congress of Academy of Insurance Medicine of Asia, Ho Chi Minh City, Vietnam, November 4-7. 2001.
- (75) "The Treatment of Chronic Hepatitis B", the Eleventh Annual Bristol-Myers Squibb Award for Distinguished Achievement in Infectious Diseases Colloquium, at Newport, USA, November 15, 2001.
- (76) "L-nucleosides", HEP DART 2001, Frontiers in Drug Development for Viral Hepatitis, Maui, Hawaii, December 16-20, 2001.
- (77) "Treatment of Chronic Hepatitis B Virus Infection", Academic Seminar of the Associação Chinesa dos Profissionais de Medicina de Macau, Macau, January 20, 2002.

(78) "Treatment of HBV Infection", the Second Asian Pacific Digestive Week Gastroenterology Postgraduate Course, World Congress of Gastroenterology, Bangkok, Thailand, February 24 – March 1, 2002.

- (79) "Clinical Application of the Line Probe Assay, Innogenetics", the HBV Distributor Training 'INNO LiPA HBV Genotyping, Precore and Resistance Testing', Innogenetics Biotechnology for Healthcare, Bankgok, Thailand, February 24, 2002.
- (80) "Therapeutics Advances in Chronic Hepatitis B: Update on Lamivudine Therapy", the Tenth International Congress on Infectious Diseases "Hepatitis disease management integrating prevention, diagnostics and therapeutics", Singapore, March 11-14, 2002.
- (81) "Treatment of HBV Infection", LG Chem Investment Ltd., Seoul, Korea, March 22, 2002.
- (82) "Clinical Outcomes with Long-term Lamivudine Therapy", the Thirty-seventh Annual Meeting of the European Association for the Study of the Liver, Madrid, Spain, April 20, 2002.
- (83) "Lamivudine 5 Years Data", the Symposium on 'Chronic Hepatitis B Management: Sharing Best Practice', the Hong Kong Association for the Study of Liver Diseases, Hong Kong, May 9, 2002.
- (84) "Natural History of Hepatitis B" and "Treatment of Hepatitis B" (Keynote Speaker), the Second Indian Ocean Conference on Viral Hepatitis organised by Fremantle Hospital and Health Services at Perth, Australia, May 25, 2002.
- (85) "Hepatitis A-G" to students of Law Ting Pong Secondary School, organized by the Hong Kong Liver Foundation, Hong Kong, May 31, 2002.
- (86) "Cost Effectiveness of Screening for Hepatocellular Carcinoma", 'Symposium in Medical Sciences 21st Century Health Care in Hong Kong: A New Era' to celebrate the Grand Opening of the Faculty of Medicine Building, The University of Hong Kong, Hong Kong, June 2, 2002.
- (87) "Advances in the Treatment of Chronic Hepatitis B with Nucleoside Analogues", the National Symposium on Diagnosis & Treatment of Liver Diseases, Lianjiang, Guangdong, China, July 7, 2002.
- (88) "Two Clinical Applications of the Line Probe Assay", Hong Kong Academy of Medicine Building, Hong Kong, September 24, 2002.
- (89) "Current Topics on the Treatment of Chronic Hepatitis B", the Sixth General Meeting of the Japanese Society of Hepatology, DDW-Japan 2002 Yokohama, October 25, 2002.
- (90) "International Multicenter Trial of LdT (Telbivudine), Alone and in Combination with Lamivudine, for Chronic Hepatitis B: An Interim Analysis", the Fifty-third Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA, November 1-5, 2002.

- (91) "New Antiviral Treatment for Chronic Hepatitis B", the First JSH Single Topic Conference "Therapy of Viral Hepatitis and Prevention of Hepatocellular Carcinoma", Mount Fuji, Japan, November 14–15, 2002.
- (92) "Covalently closed circular DNA in chronic HBV infection", 6-day workshop 'Molecular Science of Liver diseases: linking Basic Science to Clinical Application', Croucher Adanced Study Institute, Centre for the Study of Liver Disease, The University of Hong Kong, Hong Kong, January 13, 2003.
- (93) "Management of Chronic Hepatitis B Infection", Baptitis Hospital CME (Physicians) Programme, Hong Kong, February 10, 2003.
- (94) "Management of Chronic Hepatitis B", Symposium entitled 'The Management of Chronic Hepatitis B'; "Natural History, Screening and Prevention of Hepatocellular Carcinoma, Symposium entitled "Hepatocellular Carcinoma Recent Advances"; and "Treatment of Chronic Hepatitis B: Past, Present and Future", Symposium entitled 'Hepatitis B Prevention is better than Cure', the Nineteenth Annual Congress of Pakistan Society of Gastroenterology and GI Endoscopy, Lahore and Islamabad, Pakistan, February 27 –March 2, 2003.
- (95) "The Natural History of HBV: Precore Mutants and ccc HBV DNA", Gastroenterological Society of Singapore, Singapore, March 20, 2003.
- (96) "Controversies in HBV Management: To Treat or Not to Treat?", the Third Triennial International Society for Viral Hepatitis and Liver Diseases, Sydney, Australia, April 6, 2003.
- (97) "International Phase IIB Trial of LdT, and LdT plus Lamivudine, in patients with chronic hepatitis B", Workshop 'Clinical Experience with New Antivirals against HBV', the International Symposium on Viral Hepatitis & Liver Disease, Sydney, Austrialia, April 9, 2003.
- (98) "Treatment of Chronic Hepatitis B", Hong Kong College of Family Physicians, Hong Kong, August 2, 2003.
- (99) "Newer Developments of the Hepatitis B Virus Precore Mutations and HBV Genotype", the Colloquium of Bristol-Myers Squibb Company, New York, USA, October 16, 2003.
- (100) "Clinical Challenge 4: Managing Expectations from Therapy: What is the Duration of Response and When Should Therapy be Stopped?", Symposium 'Unanswered Questions in the Treatment of Chronic Hepatitis B', American Association for Study of Liver Diseases, Boston, Massachusetts, USA, October 26, 2003.
- (101) "Current Antiviral Therapy for Hepatitis B: the Perspective from Asia", Symposium 'Optmizing the management of hepatitis B 2003', American Association for Study of Liver Diseases, Boston, Massachusetts, October 27, 2003.
- (102) "Update on Non A Hepatitis", Private Practising Paediatricians Study Group, November 14, 2003.

(103) "Chronic Hepatitis B – Durability of Response to Therapy and Therapeutic End-points", International Symposium on Hepatology 2003, Hong Kong Association for the Study of Liver Diseases, Hong Kong, November 29, 2003.

- (104) "L-thymidine and related compounds", Next Generation of HBV Inhibitors Session 'HEP DART 2003, Frontiers in Drug Development for Viral Hepatitis', Hawaii, USA, December 16, 2003.
- (105) "What Should be the Endpoint of Chronic Hepatitis B Treatment?", **Plenary Session** II. Co-chaired an oral session at the Ninth Medical Research Conference, Medical Science Group, The University of Hong Kong, Hong Kong, February 8, 2004.
- (106) "Overview of New Antiviral Agents for Chronic Hepatitis B", the First International Liver Symposium for Evolving Issue in Asia-Pacific Countries on "Antiviral Therapy for Hepatitis B; Past, Present and Future", Seoul, Korea, February 12-14, 2004.
- (107) "Use of Nucleoside Analogues in Chronic Hepatitis B Virus Infection", the Hong Kong-Shanghai International Liver Congress 2004, Hong Kong, February 14-17, 2004.
- (108) "Entecavir is Superior to Lamivudine in Reducing Hepatitis B Virus DNA in Patients with Chronic Hepatitis B Infection"; and "Do Nucleoside/Nucleotide Analogues meet the management challenge?", Hong Kong-Shanghai International Liver Congress 2004, February 14-17, 2004.
- (109) 'BMS Symposium' (Chairman), Hong Kong-Shanghai International Liver Congress 2004, Hong Kong, February 14-17, 2004.
- (110) "Viral Hepatitis" (Invited Moderator Poster Discussion), Biennial Scientific Meeting of the International Association for the Study of the Liver, Salvador, Bahia, March 18-20, 2004.
- (111) "Treatment of HBV Infection", Seminar on Viral Hepatitis for Nurses 2004, Hong Kong Central Library, Hong Kong on May 15, 2004.
- (112) "New Insights in antiviral Treatment of Chronic Hepatitis B", Conference 'Advances in Medicine 2004', Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Convention and Exhibition Centre, June 19-20, 2004.
- (113) "Interpreting Abnormal Laboratory Findings", the Ninth Hong Kong Medical Forum, the Hong Kong Convention and Exhibition Centre, Hong Kong, July 18, 2004. (Cochaired with Professor Rosie Young)
- (114) "Liver Function", Session entitled 'Interpreting Abnormal Laboratory Findings', the Ninth Hong Kong Medical Forum, the Hong Kong Convention and Exhibition Centre, Hong Kong, July 18, 2004. (Joint Lecture with Dr. Yuen Man Fung)
- (115) "Update on the Nature History of Chronic Hepatitis B", Session entitled 'Emerged and Emerging Infections', the Ninth Hong Kong Medical Forum, the Hong Kong Convention and Exhibition Centre, Hong Kong, July 18, 2004.

(116) "Advances in Treatment of Hepatiits B Infection", the Alimentary Disease Weekend, Departments of Medicine & Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong, September 19, 2004.

- (117) "New Insights in Antiviral Treatment of Chronic Hepatitis B", the Asian Pacific Disgestive Week 2004, Beijing, China, October 5, 2004.
- (118) "Infective Liver Disease An Update of Epidemiology and Management" (Symposium Co-Moderator), Asian Pacific Disgestive Week 2004, Beijing, China, October 5, 2004...
- (119) "Valtorcitabine Provides Potent Suppression of Hepatitis B Virus in Patients with Chronic Hepatitis B: Results of a Phase I/II Clinical Trial", the Fifty-fifth Annual Meeting of the AASLD in Boston, Massachusettes, USA, Oct 29 Nov 2, 2004.
- (120) "Double-Blind, Placebo-Controlled Trial of Emtricitabine (FTC, Emtriva®) Administered Once-Daily for Treatment of Chronic Hepatitis B Virus (HBV) Infection", the Fifty-fifth Annual Meeting of the AASLD in Boston, Massachusettes, USA, Oct 29 Nov 2, 2004.
- (121) "Cirrhosis and Carcinoma: What are the Predictors of Progression?", Symposium "Building New Strategies in Chronic Hepatitis B", the Fifty-fifth AASLD Annual Meeting, Boston, Massachusettes, USA, Oct 29 Nov 2, 2004.
- (122) "Chemoprophylaxis for Hepatocellular Carcinoma", the Fourth International Meeting on HCC: East & Western Experiences, Hong Kong Exhibition and Convention Centre, Hong Kong, November 15 16, 2004.
- (123) "New Insights in Antiviral Treatment of Chronic Hepatitis B", the Continuing Education Seminar entitled 'Lamivudine, Adefovir and New Antiviral Agents', Pharmacy Central Continuing Education Committee, Hong Kong, November 17, 2004.
- (124) "Liver Cirrhosis and Liver Cancer", the International Forum on Liver Fibrosis 2004 jointly organised by HKU and City University of Hong Kong, Hong Kong, November 25, 2004.
- (125) "Liver cancer", the Cancer Prevention and Health Expo 2004, Lions Club of Hong Kong (Host), December 5, 2004.
- (126) "Adefovir as First Line Nucleoside Analogue for Chronic Hepatitis B: PRO", APASL-2004 Conference, New Delhi, India, December 11-15, 2004.
- (127) "Management of Asymptomatic HBsAg-positive Subjects with Normal ALT and HBV DNA >10⁵ copies/ml", APASL-2004 Conference, New Delhi, India, December 11-15, 2004.
- "Emerging Therapeutic Problems in Chronic Hepatitis B A New Treatment Option for HBeAg-negative Patients", and "New Antiviral Agents for Chronic Hepatitis B", APASL Conference, New Delhi, India, December 11-15, 2004.

- (129) "Review/Critique of studies on natural history of hepatitis B", the "AASLD-APASL Research Workshop on Epidemiology and Natural History of Liver Diseases in Asia", New Delhi, India, December 11-15, 2004.
- (130) "Chronic B Hepatitis, Management and Research Updated", Continuous Medical Education in Internal Medicine 2004/2005, Serviços de Saúde of Governo da Região Administrativa Especial de Macau, Macau on March 5, 2005.
- (131) "Treatment of HBV Infection", Seminar on Viral Hepatitis for Nurses 2005, Department of Health, Hong Kong on April 23, 2005.
- (132) "Phase II Multi-center, Dose-escalating Study of LB80380(ANA380) in Hepatitis B Patients with Lamivudine-resistant YMDD Mutant HBV", the Fortieenth Annual Meeting of the European Association for the Study of the Liver, Paris, France, April 16, 2005.
- (133) "Management of Chronic Hepatitis B and Update on Entecavir Global Studies", the Twelfth National Congress for Viral Hepatitis and Liver Diseases in Beijing, China, May 14, 2005.
- (134) "Phase IIb Extended-Treatment Trial of Telbivudine (LdT) vs. Lamivudine vs. Combination Treatment in Hepatitis B Patients: Two-Year Results", Digestive Disease Week, Chicago, Illinois, USA, May 16, 2005.
- (135) "Management of Chronic Hepatitis B and Update on Entecaivr", KASL Spring Congress 2005, Gyeongju, Korea, May 28, 2005.
- (136) "Chemoprophylaxis for Hepatocellulcar Carcinoma", the Fifth Shanghai International Conference on Gastroenterology, Shanghai, China, July 7, 2005.
- (137) "Treatment of Chronic Hepatitis B", the Fifth Shanghai International Conference on Gastroenterology, Shanghai, China, July 8, 2005.
- (138) "Treatment of Chronic Hepatitis B: New Antiviral Agents" and "Management of Chronic Hepatitis B and Update on Entecavir Global Studies", 2005 Entecavir National Train-the-Trainer Seminar, Jiu Zhai Gou, China, July 29, 2005.
- (139) "Debate: Entecavir as First Line Treatment for CHB: Pro & Cons", the Fifteenth Asian Pacific Association for the Study of the Liver (APASL), Bali, Indonesia, August 18-21, 2005.
- (140) "A New treatment Option for Chronic Hepatitis B Infection: An Update on Entecavir", symposium entitled 'Time to ACT in Hepatitis B Earlier intervention for a progressive diseases', the Fifteenth Asian Pacific Association for the Study of the Liver (APASL), Bali, Indonesia, August 18-21, 2005.
- (141) "Screening and Prevention of Liver Cancer", symposium for Medical & Health Professionals Liver Cancer: Prevention & Cure in 21st Century, the Hong Kong Anti-Cancer Society, August 27, 2005.
- (142) "Management of Hepatitis B & Update on Entecavir Global Studies", Associação Chinesa dos Profissionalis de Medicina de Macau on August 30, 2005.

(143) **State-of-the-Art (IASL) Lecture** on "HBV subtypes, genotypes and replicative states: What do they mean?", the World Congress of Gastroenterology and IASL 2005 Meeting, Montreal, Canada, 12-14 September 2005.

- (144) "Treatment of HBeAg-positive Chronic Hepatitis B Patients", the Sixth International Meeting on Therapy in Liver Diseases, Barcelona, Spain, September 28-30, 2005.
- (145) "HBV genotypes", Bristol-Myers Squibb Infectious Diseases Colloquium, New York, USA, October 20, 2005.
- (146) **Leon Schiff State-of-the-Art Lecture** "The Natural History and Treatment of Chronic Hepatitis B: Consensus and Controversies", the 56th AASLD Annual Meeting, San Francisco, USA, November 11-15, 2005.
- (147) "Telbivudine (LdT) vs. Lamivudine for Chronic Hepatitis B: First-Year Results from the International Phase III GLOBE Trial", the Fifty-sixth AASLD Annual Meeting in San Francisco, USA on November 14, 2005.
- (148) "Maximal Early HBV Suppression is Predictive of Optimal Virologic and Clinical Efficacy in Nucleoside-Treated Hepatitis B Patients: Scientific Observations from A Large Multinational Trial (the GLOBE Study)", the Fifty-sixth AASLD Annual Meeting in San Francisco, USA, November 14, 2005.
- (149) "Screening and Prevention of Liver Cancer", symposium for Medical & Health Professionals Liver Cancer: Prevention & Cure in 21st Century, the Hong Kong Anti-Cancer Society, August 27, 2005.
- (150) "New and Future Treatment Options for Chronic Hepatitis B", the Fifty-sixth AASLD Annual Meeting, San Francisco, USA, November 11-15, 2005.
- (151) "The Natural History and Treatment of Chronic Hepatitis B: Consensus and Controversies", International Symposium on Hepatology 2005, HKASLD, Hong Kong, November 25-26, 2005.
- (152) "Cancer: Scientific Meeting of the Centre for Cancer Research", the Frontiers in Biomedical Research 2005, Faculty of Medicine, The University of Hong Kong, December 2, 2005. (Co-chaired with Dr Daniel TT Chua)
- (153) "A Phase III Comparative Trial of Telbivudine (LdT) vs. Lamivudine for Chronic Hepatitis B: First-year Results from the Large International GLOBE Trial", the *Idenix/Novartis* "*Telbivudine Phase III GLOBE US HBV Experts Forum*", Hawaii, USA, December 15, 2005.
- (154) **State-of-the-Art-Lecture** "Hepatitis B Virus Subtypes, Genotypes and Replicative States: What Do They Mean?", the Seventh Annual Scientific Meeting of the Centre for the Study of Liver Disease, The University of Hong Kong, Hong Kong, January 21, 2006.
- (155) "GLOBE (007) 1 Year Results Primary Efficacy and Safety Endpoints from this Large Ph III Clinical Trial Comparing Telbivudine to Lamivudine", the Third Telbivudine Asian Expert Meeting organized by Novartis Pharmaceuticals in Seoul, Korea, January 23, 2006.

(156) "The Natural History and Treatment of Chronic Hepatitis B: Consensus and Controversies", BMS Chronic Hepatitis B Global Advisory Board Meeting, Madrid, Spain, February 10, 2006.

- (157) "Treatment of Chronic Hepatitis B: Consensus and Controversies", the 'First New Frontiers in HBV Clinical Management': GLOBE Update Meeting, Norvartis Pharmaceuticals, Bangkok, Thailand, February 17-18, 2006.
- (158) "Entecavir, Other New Oral Antiviral Drugs and Future Prospects for Therapy of CHB", the Fourteenth Indian Association for the Study of the Liver Conference", Nagpur, India, February 26, 2006.
- (159) "The role of Virus Level Reduction in Hepatitis B Management, Updates and New Treatment Options", the BMS Stand-Alone Meeting, Singapore, March 1, 2006. (Press Briefing presentation)
- (160) "Role of Antiviral Treatment for Patients with Hepatitis B related Hepatocellular Carcinoma", Singapore General Hospital, Singapore, March 1, 2006.
- (161) "Rising to the Challenge in Chronic Hepatitis B Management", the auspices of Chatper of Gastroenterologists, College of Physicians, Singapore and Gastroenterological Society of Singapore, Singapore, March 1, 2006.
- (162) "Rising to the Challenge in Chronic Hepatitis B Management", symposium entitled 'Raising a New Standard in Chronic Hepatitis B Management', Singapore, March 1, 2006.
- (163) "Telbivudine Displays Consistent Antiviral Efficacy across Patients Subgroups for the Treatment of Chronic Hepatitis B: Results from the Globe Study", the Sixthteenth Asian Pacific Association for the Study of the Liver (APASL), Manila, Philippines, March 6, 2006.
- (164) "Predictors of Viral Resistance: Conclusions from RCTs", and "HBV Genotypes: Implications in Management", the Sixteenth Asian Pacific Association for the Study of the Liver (APASL), Manila, Philippines, March 6, 2006.
- (165) "Management of Chronic Hepatitis B: Consensus and Controversies", Sixteenth Asian Pacific Association for the Study of the Liver (APASL), Manila, Philippines, March 6, 2006.
- (166) "HBV Genotypes: Implications in Management", scientific session entitled 'Clinical Symposium 9: Viral Genotyping', the Sixteenth Asian Pacific Association for the Study of the Liver (APASL), Manila, Philippines, March 7, 2006.
- (167) "Current and Future Antivirals in the Management of CHB", Satellite Symosium (II), 2006 Spring Convention of Gastroenterological Society of Taiwan, March 17, 2006.
- (168) "Management of Chronic Hepatitis B: Consensus and Controversies", Symposium 'Time, Triggers and Treatment: Turning the Tide of Hepatitis B', Shanghai-Hong Kong International Liver Congress, Shanghai, China, March 26, 2006.
- (169) "Treatment of Chronic Viral Hepatitis B & C", Seminar on Viral Hepatitis for Nurses 2006, Centre for Health Protection, Department of Health, Hong Kong, April 8, 2006.

(170) "Management of Chronic Hepatitis B: Consensum and Controversies", symposium entitled 'Time to Act in Hepatitis B: Earlier Intervention for a Progressive Disease', Malaysia, April 20, 2006.

- (171) "Phase II, Multi-centre, Dose-escalating Study of LH80380 (ANA 380) in Hepatitis B Patients with Lamivudine-resistant YMDD Mutant HBV", the Forty-first Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, April 27, 2006.
- (172) "Relevance of Viral Load in the Management of Chronic Hepatitis B", the Forty Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, April 26-30, 2006.
- (173) "The Natural History and Treatment of Chronic Hepatitis B: the Asian Perspective", BMS Scientific Meeting 'Viral Load and the Management of Chronic Hepatitis B: What Can We learn from Cohort Studies', the Forty-first Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, April 28, 2006.
- (174) "Duration of Therapy How Long Do You Treat?", BMS Satellite Symposium 'Expert Perspectives: Refining the HBV Treatment Paradigm', Digestive Disease Week, LA, USA, May 20-25, 2006.
- (175) "Duration of Therapy How Long Do You Treat?", symposium entitled 'Expert Perspectives: Refining the HBV Treatment Paradigm', Digestive Disease Week, LA, USA, May 20-25, 2006.
- (176) "New and Future Treatment Options for Chronic Hepatitis B" and co-chaired the session 'Haematology & Hepatology', the 11th Hong Kong Medical Forum, Department of Medicine, Faculty of Medicine, The University of Hong Kong, Hong Kong, June 4, 2006.
- (177) "The Natural History of Chronic Hepatitis B", **Plenary Session** entitled "HBV and HDV: Virology, Immunology, Natural History, Treatment", the Twelfth International Symposium on Viral Hepatitis and Liver Disease, Paris, July 4, 2006.
- (178) "The Natural History and Treatment of Chronic Hepatitis B: Consensus and Controversies", the "FOCUS on Hepatitis B" meeting, Shenzhen, August 26, 2006.
- (179) "Viral Load and Disease Progression"; "Understanding Viral Resistance: Impact and Importance on Treatment"; and "Treatment Guidelines: Are We Missing Patients at Risk?", BMS Chronic Hepatitis B Updates 'Evidence for Action Hope for Hepatitis B', Trengganu, Malaysia, September 2, 2006.
- (180) "Patient Case", BMS Entecavir European Launch Meeting entitled "On the Road to Optimizing HBV Treatment with Baraclude", Paris, France, September 22-23, 2006.
- (181) "Rising to the Challenge in the Management of Chronic Hepatitis B", HKASLD Scientific Symposium Programme Raising a New Standard in Chronic Hepatitis B Management, Hong Kong, September 28, 2006.
- (182) "Rising to the Challenge in the Management of Chronic Hepatitis B", DDW-Japan 2006, Sapporo, Japan, October 12, 2006.

- (183) "Understanding HBV Disease: Viral Load and Disease Progression", the Fifty-seventh AASLD, Boston, USA, October 30, 2006.
- (184) "Two-Year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine", the Fifty-seventh AASLD Annual Meeting, Boston, USA, October 27 31, 2006.
- (185) "Viral Resistance to Nucleos(t)ide Analogues and the Effect of HBV DNA Suppression", the International Symposium on Hepatology 2006, The Hong Kong Association for the Study of Liver Diseases, Hong Kong, November 3-4, 2006.
- (186) "Viral Resistance to Nucleos(t)ide Analogues Effect of HBV DNA Suppression", the KASL Autumn Symposium, Seoul, Korea, November 22, 2006.
- (187) "Clinical Applicability of the Latest AASLD / APASL Guidelines in the Asian Population", and "Role of HBV Genotypes in Managing CHB Among Asians" the First St. Luke's International Liver Conference, Manila, Philippines, January 15-16, 2007.
- (188) "Clinical Applicability of the Latest AASLD / APASL Guidelines in the Asian Population" and "Two-Year Results from the GLOBE Trial: Telbivudine (LdT) vs Lamivudine", the Telbivudine Indonesian Launch Meeting, Jarkarta, Indonesia, February 3, 2007.
- (189) "The importance of monitoring the disease", the 'Hepatitis B Awareness Campaign HK 2007', The Hong Kong Liver Foundation, Hong Kong, March 18, 2007.
- (190) "Hepatology", the Fiftieth Anniversary Scientific Meeting of the Society of Physicians of Hong Kong, March 18, 2007.
- (191) **Post Graduate Course** "HBV Treatment Update", and "Entecavir & Nucs" and "Lamivudine/Adefovir/Entecavir", the Seventh Asian Pacific Association for the Study of the Liver (APASL) Conference "Viral Hepatitis and Hepatocellular Carcinoma in Asia", Kyoto, Japan, March 27-30, 2007.
- (192) "Entecavir & Nucs" and "Lamivudine/Adefovir/Entecavir", the HBV Day of the Seventeenth Asian Pacific Association for the Study of the Liver (APASL) Conference "Viral Hepatitis and Hepatocellular Carcinoma in Asia", Kyoto, Japan, March 27-30, 2007.
- (193) "Hepatitis in Asia and its Complications", public lecture at the East-West Alliance Meeting, Faculty of Medicine, The University of Hong Kong, Hong Kong, April 14, 2007.
- (194) "Presentation on New Aspect on Anti-virals", Novartis Korea Limited 'Round-table Discussion on: New Aspects on Anti-viral Agents for Chronic Hepatitis B', Seoul, Korea, April 23-24, 2007.
- (195) "Update on Chronic Hepatitis B Treatment and Guideline", BMS Round Table Discussion, Hong Kong, April 26, 2007.
- (196) "Treatment of Chronic Hepatitis B", Seminar on Viral Hepatitis for Nurses 2007, Department of Health, Hong Kong, May 4, 2007.

(197) "Hepatitis B Virus Treatment Update", New Delhi Meeting, Delhi Society of Gastroenterology; and Novartis Standalone Meeting, Novartis India Limited, Hyderbad, India, May 6, 2007.

- (198) "Update on Chronic Hepatitis B Treatment", Symposium entitled 'The Importance of Viral Load and Hepatitis B Treatment Update', The Hong Kong Medical Association, Hong Kong, May 10, 2007.
- (199) "Who to treat? A Critical Review of Two New Treatment Guidelines from the States. Comparison of Current Treatment Options", National Hepatology Congress, Istanbul, Turkey, June 7-10, 2007.
- (200) "Comparison of Two New Guidelines of Treatment for Chronic Hepatitis B from the United States", **Plenary Session** entitled 'Antiviral treatment strategy, focusing on treatment indication, treatment duration, end point, etc.', the China National Conference on Hepatitis and Liver Disease, Shanghai, China, July 7, 2007 (Keynote speaker)
- (201) "Currently Licensed Agents and Their Comparison", symposium entitled 'Chronic Hepatitis B from the United States", China National Conference on Hepatitis and Liver Disease, Shanghai, China, July 7, 2007.
- (202) Educational forum of 'Mapping the Future Resistance Forum', Asia Pacific Resistance Advisory Board Meeting, Melbourne, Australia, July 18, 2007.
- (203) "Current and Future Strategies in Improving Treatment Outcomes in Chronic Hepatitis B", the Inaugural Conference of the Hepatology Society of Philippines, Manila, Philippines, August 4, 2007.
- (204) "Two-Year Results from the GLOBE Trial: Telbivudine (LdT) vs Lamivudine", Novartis (Sebivo) Launch Symposium of Hepatology Society of Philippines, Manila, Philippines, August 4, 2007.
- (205) "Chronic Hepatitis B Infection: (a) Critical Approach to Treatment Guidelines (b)The Telbivudine (GLOBE) Trial" at the Round Table Discussion Meeting on 'The latest approach for the management of chronic hepatitis B', the Infection Control Committee of Macau Government Hospital, Macau, August 11, 2007.
- (206) "介紹各類型肝炎" at the 全港十八區巡迴健康展覧及講座 「與我何肝」之丙型 肝炎, the Hong Kong Liver Foundation, Hong Kong,n August 18, 2007.
- (207) "Update on Hepatitis B", Medical Grand Round of Princess Margaret Hospital, Hong Kong on August 22, 2007.
- (208) "Review of Telbivudine GLOBE Trial (year 1 and year 2) and Using Baseline Predictive Results to Optimize Results in HBV Pos & Neg patients", Hong Kong
- (209) Association for the Study of Liver Diseases Symposium on 'Bridges to new ways on HBV care', Hong Kong, September 3, 2007.

- (210) "Update on Chronic Hepatitis B", Ninth Joint Annual Scientific Meeting of The Hong Kong Society of Gastroenterology, The Hong Kong Society of Digestive Endoscopy, Hong Kong Society for Coloproctology, Hong Kong Association for the Study of Liver Diseases and The Hong Kong Society of Gastrointestinal Motility, Hong Kong, September 8, 2007.
- (211) "CHB Treatment Guidelines: Do They Advance or Represent Roadblocks to Appropriate Treatment of Patients?", Fifty-eighth Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA, November 4, 2007.
- (212) "Treatment Goals: Can CHB be Cured?" and "Emerging Therapy for Chronic Hepatitis B", APASL Single Topic Conference on Innovative of CHB Management, Pattaya, Thailand, November 22, 2007.
- (213) "Emerging Therapy for Chronic Hepatitis B", International Symposium on Hepatology 2007, Hong Kong, November 23-24, 2007.
- (214) "Discovery and Prospects for New HBV Therapy", Eighteenth Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, March 23-26, 2008.
- (215) "96 Weeks of Entecavir (ETV) Re-treatment of HBeAg(-) ETV Patients who Previously Discontinued Treatment", Eighteenth Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, March 23-26, 2008.
- (216) "Emerging Therapy for Chronic Hepatitis B" at the **Postgraduate Course** 2: Overview of Hepatitis B and "Discovery and Prospects for New HBV Therapy", the Eighteenth Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, March 23-26, 2008.
- (217) Co-chaired at the Postgraduate Course 2: Overview of Hepatitis B and Poster Presentation & Exhibition I: Poster Presentation 2: Hepatitis B (II) at the 18th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Seoul, Korea between March 23-26, 2008.
- (218) Consultant for the Bristol-Myers Squibb FACE B Speakers Faculty to give presentations of "Baraclude FAQs" (speaker backup) deck at the FACE B Speaker Training and "Resistance at 96 Weeks" deck respectively in California and Los Angeles, USA, May 3-7, 2008.
- (219) "Optimal Screening Programme for HCC in Endemic Areas" at the session 'Plenary I Early Diagnosis of Prevalent Cancers: Screening and Imaging', Inaugural William and Elizabeth Davies Foundation Trust International Meeting, the Royal College of Physicians and Surgeons of Glasgow and the Hong Kong College of Physicians, Hong Kong, May 10-11, 2008.
- (220) "Advances in the CHB Treatment Strategy", Hongkong-shenzhen Communication Conference on CHB Management in Shenzhen, China, May 24, 2008.
- (221) "CHB Natural History and Treatment Paradigm", the Baraclude (Entecavir) Speaker Training Program 'Evolving Treatment Paradigms in CHB' and "Treatment Paradigms in CHB", Symposium for Singapore Physicians in Singapore, June 6, 2008.

(222) Participated in the Baraclude Global Advisory Board Meeting, Hong Kong between June 10-11, 2008.

- (223) "How can we Achieve the Best End point of CHB Management", Guangdong Medical Association of Hepatology in Guangzhou, China, July 4-6, 2008.
- (224) "Management of Hepatitis B: the Champion's Approach in 2008" **State-of-the-Art Lecture** at the conference "Winning Concepts of Gastroenterology and Hepatology: the View of International Experts', Johns Hopkins University School of Medicine and Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, August 3-5, 2008.
- (225) "What is the Best Treatment Endpoint for CHB Management?", the Third B Foucs Conference, Chinese Infectious Disease Assocation, Beijing, China, October 18-19, 2008.
- (226) "Screening of HCC in China and Managing High Risk Patient Groups" (Keynote speaker), the Sixth Australian Viral Hepatitis Conference, Brisbane, Australia, October 20-22, 2008.
- (227) "Management of Hepatitis B: the Approach in 2008 Modern Endpoints for HBV Treatment", the **Postgraduate Course**, the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, USA, October 31 November 4, 2008.
- (228) "HBV: Who to Treat, When to Treat and What Drug?", the **Postgraduate Course**, the Fifty Anniversary of International Association for the Study of the Liver in tandem with the Fifty-ninth Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, USA, October 31 to November 2, 2008.
- (229) Case-based Presentation on "Management of Suboptimal Response", AASLD Satellite Symposium entitled 'HBV Providers' Choice in "PRIME" Time: Addressing Issues of <u>Patient Populations</u>, <u>Resistance</u>, <u>Individualized Treatment</u>, <u>Management</u>, and Efficacy', San Francisco, CA, USA, November 2, 2008.
- (230) "Treatment End Points: Translating Clinical Trials into Clinical Practice", Second Ditan International Conference on Infectiuos Diseases, Beijing, China, November 15, 2008.
- (231) "HBV: Who to Treat, When to Treat and With What Drug?, GSK CHB Evening Symposium, Hong Kong, November 21, 2008.
- (232) "HBV: Who to Treat, When to Treat and With What Drug?, Symposium of Infection Control Association of Macao, Macau, November 28, 2008.
- (233) International Conference: Infection and Cancer: Biology, Therapeutics, and Prevention [Cancer Screening Session Chairperson (co-chaired with Dr. Vincent W. S. Wong of CUHK), American Association for Cancer Research (AACR) at the on December 6, 2008.
- (234) "Managing Primary Nonresponse/Relapse to Antivirals in CHB" (**Plenary Lecture**), and "Treatment Approach of a Patient with CHB", Meet the Experts Forum, Second St. Luke's International Liver Conference, Manila, Philippines, January 19-20, 2009.

(235) "New Approaches to Monitoring HBV-DNA During Hepatitis B Treatment", Roche Diagnostic Satellite Symposium, 19th Conference of the APASL, 2009, Hong Kong, February 13, 2009.

- (236) "Short-term Treatment Goals: Reflections on HBeAg Seroconversion", Meet-the-Expert Session, APASL 2009, Hong Kong, February 13, 2009.
- (237) "Management of Chronic Hepatitis B", Infectious Disease Conference 2009, Hospital Authority Infectious Disease Control Training Centre, Hospital Authority Infectious Disease Centre & Johns Hopkins University on February 21, 2009.
- (238) "Treatment of Chronic Hepatitis B Virus", Seminar on Viral Hepatitis for Nurses 2009, Centre for Health Protection, Department of Health, Hong Kong, March 26, 2009.
- (239) "Management of Hepatitis B Infection", British Infection Society Trainees' Day, London, United Kingdom on May 14, 2009.
- (240) "Management of Primary Non-response and Resistance to Antiviral Therapy for Chronic Hepatitis B", the Twelfth Annual Meeting of the British Infection Society, London, United Kingdom, May 15, 2009.
- (241) Gastroenterology & Hepatology Module of the Postgraduate Diploma in Diagnosis and Therapeutics in Internal Medicine, Department of Medicine, the University of Hong Kong, Hong Kong, June 13-14, 2009.
- (242) "Long Term Data for Oral Anti Virals in CHB Treatment", Bristol-Myers Squibb Round-table Meeting, Hong Kong, June 19, 2009.
- (243) "Chronic Hepatitis B: Natural History, Treatment Guidelines and Treatment Options Focus: Asian-Pacific Region", AiCuris GmbH & Co. KG, Wuppertal, Germany, August 14, 2009.
- (244) "Reinventing Chronic Hepatitis B in Canada", Gilead Sciences Canada Inc., Vancouver, Toronto and Montreal, Canada, October 2-6, 2009.
- (245) 'Cases Studies and Panel Discussion' (Facilitator), Evening Symposium, GlaxoSmithKline, Hong Kong, October 15, 2009.
- (246) "Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B Patient", Sixteenth Hong Kong International Cancer Congress/Sixth Annual Meeting of Cetnre for Cancer Research, Centre for Cancer Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, November 4-6, 2009.
- (247) "Occult Hepatitis B Infection: Incidence, Detection and Clinical Implications", International Symposium on Hepatology 2009/Twenty-second Annual Scientific Meeting of the Hong Kong Association for the Study of Liver Diseases in Hong Kong, November 8, 2009.
- (248) "Occult hepatitis B Infection: Incidence, Detection and Clinical Implications", **Plenary Session**: TTI, the XXth Regional Congress of the International Society of Blood Transfusion (ISBT), Asia, Nagoya, Japan, November 17, 2009.

- (249) "Antiviral Therapy for Chronic Hepatitis B: Resistance, Fibrosis, Clinical Trials with Entecavir", Scientific Meeting From durable viral suppression to disease regression, Hong Kong Association for the Study of Liver Diseases and Hong Kong Medical Association, Hong Kong, November 26, 2009.
- (250) "Antiviral Therapy for Chronic Hepatitis B: Resistance, Fibrosis, Clinical Trials with Entecavir", Symposium of Infection Control Association of Macao, Macau, January 8, 2010.
- (251) "Monitoring and Minimizing Resistance to Antiviral Therapy in Chronic Hepatitis B", the 20th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Beijing, China, March 26, 2010.
- (252) "Duration of Therapy for Chronic Hepatitis B", GSK Evening Symposium, Hong Kong, April 29, 2010.
- (253) "Management of Chronic Hepatitis B", 15th Hong Kong Medical Forum. Faculty of Medicine, The University of Hong Kong, Hong Kong, May 8-9, 2010.
- (254) "Management of Chronic Hepatitis B", Seminar on Viral Hepatitis for Nurses 2010, Department of Health, Hong Kong, May 13, 2010.
- (255) "乙型肝炎", Hepatitis B Public Education Outreach Program, The Hong Kong Liver Foundation, Hong Kong, May 16, 2010.
- (256) Bristol Myers Squibb FACE B Speaker Training Meeting in Hoboken, NJ; Manhattan; Brooklyn; and Chicago; USA, May 21-26, 2010.
- (257) "Immunosuppression and Reactivation of Chronic Hepatitis B", 14th Congress of Asia Pacific League of Associations for Rheumatology (APLAR 2010), Hong Kong, July 11-15, 2010.
- (258) "Management of Chronic Hepatitis B Infection", State-of-the-Art Lecture, Falk Symposium Gut and Liver, Beijing, China, August 27-28, 2010.
- (259) Speaker Consultant to give Baraclude slide presentations at the FACE B Speaker Programs in New York, Boston, San Francisco and Los Angeles, USA as organized by Bristol-Myers Squibb Company between October 25th to 28th 2010.
- (260) Attended the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and the Postgraduate Course "Viral Hepatitis: Five Decades of Progress and Promises for the Future", Boston, USA, between October 29 November 2, 2010.
- (261) "An update on hepatitis B and its current management", Seminar of Infection Control Association of Macao, Macau, October 15, 2010.
- (262) "The third first line agent", International Symposium on Hepatology 2010, The Hong Kong Association for the Study of Liver Diseases, Hong Kong, November 21, 2010.
- (263) "A critical review of the treatment guidelines of chronic hepatitis B" and "Drug-resistant mutants the Achilles heel of therapy: management and newer anti-virals in pipeline", 3rd Kolkata Liver Meeting, Kolkata, India, December 3-5, 2010.

- (264) Co-panelist at the Case Discussion Session "Discussion: Challenging cases of CHB and CHC" and co-chaired a concurrent symposium 'Uncommon hepatitis C virus genotypes', 21st International Conference of the Asian Pacific Association for Studies of the Liver (APASL), Bangkok, Thailand, February 17-20, 2011.
- (265) "Optimal management in 2011 and beyond", Bristol-Myers Squibb Satellite Symposium, 21st International Conference of the Asian Pacific Association for Studies of the Liver (APASL), Bangkok, Thailand, Feb 17-20, 2011.
- (266) "The evolving future of hepatitis B treatment: latest thinking and emerging practice", Gilead Satellite Symposium, 21st International Conference of the Asian Pacific Association for Studies of the Liver (APASL), Bangkok, Thailand, Feb 17-20, 2011.
- (267) "Optimal treatment of chronic hepatitis B with long-term therapy", Post APASL/EASL Symposium, Kaohsiung, Taiwan, April 16, 2011.
- (268) "Baraclude Asian cohort efficacy, resistance and histology data and Hong Kong 4 years real life data", BMS Symposium 'Hepatitis B treatment: a closer look at Asian patients', Seoul, Gwangju, Daejeon and Incheon, Korea, April 19-23, 2011.
- (269) "The evolving strategies in drug resistance management", GSK CHB evening symposium, Hong Kong, April 28, 2011.
- (270) "Once again: hepatitis B, hepatitis B & hepatitis B??!", Research Meeting, Grand Round, Department of Medicine, The University of Hong Kong, Hong Kong, April 30, 2011.
- (271) "Optimal Treatment of Chronic Hepatitis B with Long-term Therapy", Seminar on Viral Hepatitis for Nurses, Centre for Health Protection, Hong Kong Central Library, Hong Kong, May 19, 2011.
- (272) "Durability of HBeAg Seroconversion", Gilead Medical Affairs Advisory Program entitled 'When to Stop Therapy in Chronic Hepatitis B', San Francisco, USA, June 16-17, 2011.
- (273) "The long-term management of CHB patients insights obtained from special population", HKASLD Expert Meeting: Trouble-free management of hepatitis B patients, Hong Kong, July 5, 2011.
- (274) "HBV vaccination and antiviral therapy", Fifth International Liver Cancer Association (ILCA) Annual Conference, Hong Kong, September 2-4, 2011.
- (275) "Prevention of hepatocellular carcinoma: HBV vaccination and anti-viral therapy", State Key Laboratory for Liver Research (SKLLR) Symposium, The University of Hong Kong, Hong Kong, September 24, 2011.
- (276) "The etiology of 'cryptogenic' hepatocellular carcinoma", International Symposium on Hepatology 2011, 24th Annual Scientific Meeting, The Hong Kong Association for the Study of Liver Diseases, Hong Kong, November 20, 2011.
- (277) "What treatment outcomes could lead to stopping antiviral therapy in CHB?", Asia Hepatology Perspectives Forum Long-term treatment and disease outcomes in chronic hepatitis B, Hong Kong, November 26-27, 2011.

- (278) Co-chair [with Yogesh K Chawla (Chandigarh)], Symposium 2: HCC pathogenesis, 9th APASL STC Hepatocellular Carcinoma: From Basics to Cure, Jeju, Korea, December 1-3, 2011.
- (279) "The Future Development in Hepatology", 30th Anniversary Scientific Meeting of the Hong Kong Society of Gastroenterology, Hong Kong, December 9, 2011.
- (280) Co-chair the MSD Asia Pacific HCV Speakers' Forum: Evolving Concepts in HCV Therapy; and co-chair the talk entitled "Welcome & Overview: Day 1 Review Program Agenda and Objectives", Hong Kong, December 10-11, 2011.
- (281) "Recent Controversies in the Management of Hepatitis B Patients", the MSGEH Expert Meeting, Macau, January 13, 2012.
- (282) "Current therapy of chronic hepatitis B nucleos(t)ide analogues and drug resistance", **Plenary Lecture and Postgraduate Course** at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), Taipei, Taiwan, February 16th 19th, 2012.
- (283) "Making headway long-term Asian data from clinical trials and clinical practice", BMS Sponsored Satellite Symposium at the 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012), Taipei, Taiwan, February 16th 19th, 2012.
- (284) "New and future treatment for chronic hepatitis C", Infection Control Association of Macao, Macau, March 16, 2012.
- (285) "Current therapy of chronic hepatitis B: nucleos/tide analogues and drug resistance", Baraclude High 5 Symposium, Korea, between March 26-29, 2012.
- (286) "Management of HBV in patients on immunosuppressants", Multi-specialty Medical Mega Conference 2.0, Hong Kong, between April 14-15, 2012.
- (287) "Resistance Considerations in CHB Management", Gilead Post-EASL Regional Advisory Programs, in San Francisco, Costa Mesa, Los Angeles, and New York, USA, between May 5-9, 2012.
- (288) "When can we stop anti-viral agents for chronic hepatitis B", the 17th Hong Kong Medical Forum, Hong Kong, between May 12-13, 2012.
- (289) "Current Therapy of Chronic Hepatitis B", B-Focus in China organized by Chinese Journal of Infectious Diseases, Guangzhou, China on May 19-20, 2012.
- (290) "The Acronym Quartet: CHB, cccDNA, OHB & HCC", Grand Round Research Meeting, Department of Medicine, The University of Hong Kong, Hong Kong on May 26, 2012.
- (291) "Current Therapy of Chronic Hepatitis B", 2nd Wave B-Bridge in China, Chengdu and Shenyang on May 29 & 30, 2012 respectively.
- (292) Co-chair the symposium "Update on Hepatitis B", 15th International Congress on Infectious Diseases (ICID), Bangkok, Thailand between June 13-16, 2012.

(293) "Treating hepatitis B in 2012", **Plenary Lecture** at 15th International Congress on Infectious Diseases (ICID), Bangkok, Thailand between June 13-16, 2012.